

Key: 387 — Jan Helsel

Access DB# 130535

## SEARCH REQUEST FORM

### Scientific and Technical Information Center

Requester's Full Name: Sebcha Coz Examiner #: 74141 Date: 6/23/04  
Art Unit: 1616 Phone Number 30 20622 Serial Number: 10/627 926  
Mail Box and Bldg/Room Location: \_\_\_\_\_ Results Format Preferred (circle):  PAPER  DISK  E-MAIL  
4C70, Rev, 4A45

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc. if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Heterocyclic Compd - - -  
Inventors (please provide full names): Lohray et al

Earliest Priority Filing Date: Reissue of US 6,310,069

\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Reissue of US Pat. 6,310,069.  
New cl 25 added, drawn to  
specific compds covered by formula  
(III) ??  
Please search for compds of  
formula (III) in cl. 1.

STAFF USE ONLY		Type of Search	Vendors and cost where applicable
Searcher:	<u>Jan</u>	NA Sequence (#)	STN <input checked="" type="checkbox"/>
Searcher Phone #:	<u>22504</u>	AA Sequence (#)	Dialog _____
Searcher Location:		Structure (#)	Questel/Orbit <input checked="" type="checkbox"/>
Date Searcher Picked Up:	<u>8/29</u>	Bibliographic	Dr. Link _____
Date Completed:	<u>8/24</u>	Litigation	Lexis/Nexis _____
Searcher Prep & Review Time:		Fulltext	Sequence Systems _____
Clerical Prep Time:	<u>45</u>	Patent Family	WWW/Internet _____
Online Time:	<u>140</u>	Other	Other (specify) _____

blood samples were collected one hour after administration of test compounds/vehicle for assessing the biological activity.

Test compounds were suspended on 0.25% carboxymethyl cellulose and administered to test group at a dose of 10 mg to 100 mg/kg through oral gavage daily for 6 days. The control group received vehicle (dose 10 ml/kg). Troglitazone (100 mg/kg, daily dose) was used as a standard drug which showed 28% reduction in random blood sugar level on 6th day.

The blood sugar and triglycerides lowering activities of the test compound was calculated according to the formula:

$$\text{Blood sugar/triglycerides lowering activity (\%)} = 1 - \frac{DT/DC}{TC/ZC} \times 100$$

ZC=Zero day control group value

DC=Zero day treated group value

TC=Control group value on test day

DT=Treated group value on the test day

No adverse effects were observed for any of the mentioned compounds of invention in the above test.

The compounds of the present invention also showed cholesterol lowering activity in the experimental animals used.


Compound	Dose mg/kg/da	Days treated	Maximum reduction in blood glucose level (%)	Triglyceride lowering (%)
Example 3	100	6	67	12
Example 6	100	6	41	31
Example 7	100	6	66	35
Example 9	30	6	46	35
Example 12	100	6	71	57
Example 13	100	6	52	57
Example 17	30	6	65	45
Example 19	30	6	73	70
Example 21	30	6	64	76
Example 22	30	6	55	41
Example 24	10	6	63	17
Example 11	30	6	32	42
Example 28	10	6	63	57

The experimental results from the db/db mice suggest that the novel compounds of the present invention also possess therapeutic utility as a prophylactic or regular treatment for obesity, cardiovascular disorders such as hypertension, hyperlipidaemia and other diseases; as it is known from the literature that such diseases are interrelated to each other.

What is claimed is:

1. An intermediate of formula (III)

(III)



10

where G represents  $-\text{CHO}$ ,  $-\text{NH}_2$ ,  $-\text{CH}=\text{NOH}$ ,  $-\text{CH}_2\text{NHOH}$ ,  $-\text{CH}_2\text{N}(\text{OH})\text{CONH}_2$  or  $-\text{CH}_2\text{CH}(\text{J})\text{COOR}$ , wherein J represents hydroxy or halogen atom and R represents hydrogen, or lower alkyl group; and of X, Y and Z represents  $\text{C}=\text{O}$  or  $\text{C}=\text{S}$  and one of the remaining of X, Y and Z represents a group  $\text{C}=\text{}$  and the other of the remaining of X, Y or Z represents  $\text{C}=\text{C}$ ; with a proviso that when cyclic structure represented by X, Y and N form a pyrimidinone group, G does not represent CHO, R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are the substituents either on X, Y or Z or on a nitrogen atom and are the same or different and represent hydrogen atom, halogen, hydroxy or nitro, or optionally substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, heterocycl, heteroaryl, heteroaralkyl, acyl selected from acetyl, propionyl or benzoyl; acyloxy selected from acetoxy, propionyloxy, or benzoxyloxy; hydroxyalkyl, amino, acylamino, arylamino, aminoalkyl, aryloxy, alkoxycarbonyl, alkylamino, alkoxyalkyl, thioalkyl, alkylthio or carboxylic acid or its amides or sulfonic acid or its amides with the proviso that when R<sup>1</sup>, R<sup>2</sup> or R<sup>3</sup> is on a nitrogen atom it does not represent hydrogen, halogen, hydroxy, nitro; or substituted or unsubstituted aryloxy, alkoxy, cycloalkoxy, acyloxy selected from acetoxy, propionyloxy, or benzoxyloxy; alkylthio, carboxy or sulfonic acid groups; or any two of R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> along with the adjacent atoms to which they are attached may form a substituted or unsubstituted cyclic structure of 4 to 7 atoms, with one or more double bonds, which are carbocyclic or optionally contain one or more heteroatoms selected from oxygen, nitrogen and sulfur; the linking group represented by  $-(\text{CH}_2)_n-\text{O}-$  is attached either through nitrogen atom or through X, Y or Z, where n is an integer ranging from 1-4; and Ar represents an optionally substituted divalent aromatic or heterocyclic group.

45

2. A pharmaceutical composition which comprises, a compound according to claim 1 as an effective ingredient and a pharmaceutically acceptable carrier, diluent or excipient.

\* \* \* \* \*

=> d his

(FILE 'HOME' ENTERED AT 14:07:04 ON 24 AUG 2004)  
SET COST OFF

FILE 'REGISTRY' ENTERED AT 14:07:14 ON 24 AUG 2004

L1 STR  
L2 0 S L1 CSS SAM  
L3 STR L1  
L4 SCR 2039 OR 2127 OR 0250 OR 2049 OR 2048 OR 2053 OR 2052 OR 205  
L5 SCR 1993 AND 1839  
L6 SCR 1406 OR 382 OR 356  
L7 0 S L3 AND L5 AND L6 NOT L4 CSS SAM

FILE 'HCAPLUS' ENTERED AT 14:21:58 ON 24 AUG 2004

L8 4 S (US6310069 OR US6114526 OR US5985884 OR US5885997) /PN OR IN96  
E LOHRAY V/AU  
L9 47 S E4-E10  
E LOHRAY B/AU  
L10 121 S E4-E10  
E PARASELLI R/AU  
L11 12 S E4  
E GURRAM R/AU  
L12 11 S E4  
E RAMANUJAM R/AU  
L13 48 S E3,E4  
E CHAKRABARTI R/AU  
L14 154 S E3-E7,E15-E16  
E PAKALA S/AU  
L15 3 S E5  
E REDDY/AP,CS  
E REDDY/PA,CS  
L16 385 S E3-E61  
E DR REDDY/PA,CS  
L17 55 S E5-E37  
L18 4 S L8 AND L9-L17  
SEL RN

FILE 'REGISTRY' ENTERED AT 14:27:49 ON 24 AUG 2004

L19 123 S E1-E123  
L20 47 S L19 AND NCNC3-C6/ES  
L21 41 S L20 AND 46.150.18/RID  
L22 13 S L21 AND 3/NR  
L23 11 S L22 NOT NITRO  
L24 76 S L19 NOT L20  
L25 51 S L24 AND NCNC3/ES  
L26 44 S L25 AND 46.150.18/RID  
L27 17 S L26 AND 2/NR  
L28 16 S L27 NOT NITRO  
L29 9 S L28 NOT ALDEHYDE  
L30 3 S L29 AND (C12H12N2O OR C15H15N3O4)  
L31 1 S L29 AND C16H21N3O3  
L32 5 S L29 NOT L30,L31  
L33 56 S L19 AND S/ELS  
L34 53 S L33 AND 46.150.18/RID  
L35 2 S L34 AND SC4-NCNC3/ES  
L36 1 S L35 AND 3/NR  
L37 12 S L19 AND NCNC3/ES AND 46.150.18/RID AND 2/NR NOT L32  
L38 2 S L37 AND (C16H21N3O3 OR C16H19N3O3)  
L39 100 S L19 AND 46.150.18/RID  
L40 57 S L39 AND ETHOXY  
L41 15 S L40 AND ALDEHYDE  
L42 1 S C17H15N3O3 AND L41

L43 42 S L40 NOT L41  
 L44 14 S L43 NOT NCSC2/ES  
 L45 19 S L23,L32,L36,L38  
 L46 81 S L39 NOT L45  
 L47 29 S L46 NOT S/ELS  
 L48 24 S L47 NOT NITRO  
 L49 23 S L48 NOT ACETAMIDE  
 L50 19 S L49 NOT NCOC2/ES  
 L51 15 S L50 AND NR>=2  
 L52 11 S L51 NOT NOCNC/ES  
 L53 20 S L45,L42

FILE 'HCAOLD' ENTERED AT 15:01:23 ON 24 AUG 2004  
 L54 0 S L53

FILE 'HCAPLUS' ENTERED AT 15:01:26 ON 24 AUG 2004  
 L55 5 S L53  
 L56 5 S L55 AND L8-L18

FILE 'USPATFULL, USPAT2' ENTERED AT 15:02:09 ON 24 AUG 2004  
 L57 9 S L53

FILE 'REGISTRY' ENTERED AT 15:05:28 ON 24 AUG 2004

FILE 'HCAPLUS' ENTERED AT 15:06:55 ON 24 AUG 2004

FILE 'USPATFULL, USPAT2' ENTERED AT 15:07:43 ON 24 AUG 2004

FILE 'REGISTRY' ENTERED AT 15:36:06 ON 24 AUG 2004  
 L58 STR L3  
 L59 1 S L58 AND L5 AND L6 NOT L4 SAM

FILE 'HCAPLUS' ENTERED AT 15:43:05 ON 24 AUG 2004  
 E DIABETES/CT

L60 12433 S E4+OLD,NT,PFT,RT  
 L61 79998 S E12+OLD,NT,PFT,RT  
 L62 10753 S E3  
 E E3+ALL  
 E E2+ALL  
 L63 10753 S E3  
 E E3+ALL  
 E E3+ALL  
 E E19+ALL  
 L64 9093 S E5,E6,E4  
 E E10+ALL  
 E E17+ALL  
 L65 15493 S E4,E5,E3,E13

FILE 'REGISTRY' ENTERED AT 15:44:53 ON 24 AUG 2004  
 L66 3 S INSULIN/CN OR GLUCOSE/CN

FILE 'HCAPLUS' ENTERED AT 15:44:59 ON 24 AUG 2004  
 L67 238719 S L66  
 L68 167931 S ?INSULIN?  
 L69 86208 S L60-L65  
 L70 386550 S GLUCOSE OR BLOOD SUGAR  
 L71 55633 S L67,L68,L70 AND L69  
 L72 86208 S L69,L71  
 L73 47745 S L72 AND (PY<=1996 OR PRY<=1996 OR AY<=1996)  
 L74 1698 S L73 AND HET?/SC,SX  
 L75 4703 S L73 AND P/DT  
 L76 5044 S L74,L75  
 L77 5044 S L76 OR L76

L78 500 S L77 RAN=(1998:239219,)  
 L79 500 S L77 RAN=(1997:356528,1998:239217)  
 L80 500 S L77 RAN=(1996:211894,1997:354052)  
 L81 500 S L77 RAN=(1994:631055,1996:211760)  
 L82 500 S L77 RAN=(1992:563880,1994:628810)  
 L83 500 S L77 RAN=(1990:151885,1992:557663)  
 L84 500 S L77 RAN=(1986:553495,1990:151877)  
 L85 500 S L77 RAN=(1981:587068,1986:553059)  
 L86 1044 S L77 NOT L78-L85

FILE 'REGISTRY' ENTERED AT 15:52:11 ON 24 AUG 2004

FILE 'HCAPLUS' ENTERED AT 15:52:11 ON 24 AUG 2004

L87 SET SMARTSELECT ON  
 SEL L86 1- RN : 20641 TERMS  
 SET SMARTSELECT OFF

L88 FILE 'REGISTRY' ENTERED AT 15:52:46 ON 24 AUG 2004  
 20640 S L87

FILE 'HCAPLUS' ENTERED AT 15:53:56 ON 24 AUG 2004  
 SET SMARTSELECT ON

L89 SEL L85 1- RN : 15095 TERMS  
 SET SMARTSELECT OFF

L90 FILE 'REGISTRY' ENTERED AT 15:54:15 ON 24 AUG 2004  
 15094 S L89

FILE 'HCAPLUS' ENTERED AT 15:55:03 ON 24 AUG 2004  
 SET SMARTSELECT ON

L91 SEL L84 1- RN : 13449 TERMS  
 SET SMARTSELECT OFF

L92 FILE 'REGISTRY' ENTERED AT 15:55:20 ON 24 AUG 2004  
 13448 S L91

FILE 'HCAPLUS' ENTERED AT 15:56:01 ON 24 AUG 2004  
 SET SMARTSELECT ON

L93 SEL L83 1- RN : 16048 TERMS  
 SET SMARTSELECT OFF

L94 FILE 'REGISTRY' ENTERED AT 15:56:18 ON 24 AUG 2004  
 16048 S L93

FILE 'HCAPLUS' ENTERED AT 15:57:05 ON 24 AUG 2004  
 SET SMARTSELECT ON

L95 SEL L82 1- RN : 10369 TERMS  
 SET SMARTSELECT OFF

L96 FILE 'REGISTRY' ENTERED AT 15:57:21 ON 24 AUG 2004  
 10369 S L95

FILE 'HCAPLUS' ENTERED AT 15:57:54 ON 24 AUG 2004  
 SET SMARTSELECT ON

L97 SEL L81 1- RN : 17667 TERMS  
 SET SMARTSELECT OFF

L98 FILE 'REGISTRY' ENTERED AT 15:58:15 ON 24 AUG 2004  
 17667 S L97

FILE 'HCAPLUS' ENTERED AT 15:59:15 ON 24 AUG 2004  
 SET SMARTSELECT ON

L99 SEL L80 1- RN : 15411 TERMS

SET SMARTSELECT OFF

FILE 'REGISTRY' ENTERED AT 15:59:36 ON 24 AUG 2004  
 L100 15411 S L99

FILE 'HCAPLUS' ENTERED AT 16:00:21 ON 24 AUG 2004  
 L101 SET SMARTSELECT ON  
 SEL L79 1- RN : 23067 TERMS  
 SET SMARTSELECT OFF

FILE 'REGISTRY' ENTERED AT 16:00:47 ON 24 AUG 2004  
 L102 23067 S L101

FILE 'HCAPLUS' ENTERED AT 16:01:51 ON 24 AUG 2004  
 L103 SET SMARTSELECT ON  
 SEL L78 1- RN : 30314 TERMS  
 SET SMARTSELECT OFF

FILE 'REGISTRY' ENTERED AT 16:02:21 ON 24 AUG 2004  
 L104 30314 S L103

FILE 'HCAPLUS' ENTERED AT 16:03:45 ON 24 AUG 2004  
 L105 546 S L8-L18,L56 NOT L76

FILE 'REGISTRY' ENTERED AT 16:04:14 ON 24 AUG 2004

FILE 'HCAPLUS' ENTERED AT 16:04:17 ON 24 AUG 2004  
 L106 SET SMARTSELECT ON  
 SEL L105 1- RN : 13464 TERMS  
 SET SMARTSELECT OFF

FILE 'REGISTRY' ENTERED AT 16:04:43 ON 24 AUG 2004  
 L107 13464 S L106

151807 S L88,L90,L92,L94,L96,L98,L100,L102,L104,L107  
 L109 1 S L11 CSS SAM SUB=L108  
 L110 155 S L11 CSS FUL SUB=L108  
 SAV L110 QAZI697/A  
 SAV L19 QAZI697A/A

L111 126 S L110 NOT L19  
 L112 1 S L111 AND NCNC3/ES  
 L113 5 S L111 AND NCNC3-C6/ES  
 L114 0 S L111 AND NCNC3-NC5/ES  
 L115 2 S L58 SAM SUB=L110  
 L116 101 S L58 FUL SUB=L110  
 SAV L116 QAZI697B/A

L117 66 S L116 NOT L19,L112,L113  
 L118 41 S L117 NOT PIPERAZIN?  
 L119 34 S L118 NOT PYRAZOL?  
 L120 9 S L119 NOT IMIDAZOL?  
 L121 2 S L118 AND NCNC2-NC5/ES  
 L122 8 S L112,L113,L121  
 L123 64 S L117 NOT L122

FILE 'HCAPLUS' ENTERED AT 16:18:47 ON 24 AUG 2004  
 L124 6 S L122  
 L125 4 S L124 AND (PY<=1996 OR PRY<=1996 OR AY<=1996)  
 L126 2 S L124,L125 AND L8-L18  
 L127 4 S L124,L125 NOT L126

=&gt; fil reg

FILE 'REGISTRY' ENTERED AT 16:20:06 ON 24 AUG 2004  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 AUG 2004 HIGHEST RN 731771-88-3  
DICTIONARY FILE UPDATES: 23 AUG 2004 HIGHEST RN 731771-88-3


TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2001

Please note that search-term pricing does apply when conducting Smart SELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at: <http://www.chem.ubc.ca/prop/>

=> d 11  
L1 HAS NO ANSWERS  
L1 STR



REP G1=(1-4) CH2  
VAR G2=CHO/N/17/20/26/6

VAR G3=X/OH

VAR G4=OH/16

#### NODE ATTRIBUTES:

CONNECT IS M1 E

```
CONNECT IS M1 RC AT 4
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS M2 N AT 1
```

## GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 25

#### STEREO ATTRIBUTES: NONE

=> d ide can tot 1122

L122 ANSWER 1 OF 8 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 471907-41-2 REGISTRY

CN 4 (3H)-Pyrimidinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl-6-phenyl- (9CI)  
 (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C20 H21 N3 O2  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL  
 DT.CA CAplus document type: Patent  
 RL.P Roles from patents: RACT (Reactant or reagent)




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:310927

L122 ANSWER 2 OF 8 REGISTRY COPYRIGHT 2004 ACS on STN  
 RN 220746-27-0 REGISTRY  
 CN Benzenepropanoic acid, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C19 H18 N2 O5  
 SR CA  
 LC STN Files: CA, CAPLUS, USPATFULL  
 DT.CA CAplus document type: Patent  
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 130:196665

L122 ANSWER 3 OF 8 REGISTRY COPYRIGHT 2004 ACS on STN  
 RN 220746-26-9 REGISTRY  
 CN Benzenepropanoic acid, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]- $\alpha$ -hydroxy-, ethyl ester (9CI) (CA INDEX NAME)

FS 3D CONCORD  
 MF C21 H22 N2 O5  
 SR CA  
 LC STN Files: CA, CAPLUS, USPATFULL  
 DT.CA CAplus document type: Patent  
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES  
 (Uses)




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 130:196665

L122 ANSWER 4 OF 8 REGISTRY COPYRIGHT 2004 ACS on STN  
 RN 194713-71-8 REGISTRY  
 CN Benzaldehyde, 4-[2-[(1,4-dihydro-4-oxo-1-(2-pyridinyl)-3(2H)-quinazolinyl]ethoxy]- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C22 H19 N3 O3  
 SR CA  
 LC STN Files: CA, CAPLUS, USPATFULL  
 DT.CA CAplus document type: Patent  
 RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 127:205585

L122 ANSWER 5 OF 8 REGISTRY COPYRIGHT 2004 ACS on STN

RN 194713-70-7 REGISTRY  
 CN Benzaldehyde, 4-[2-(1,4-dihydro-1-methyl-4-oxo-3(2H)-quinazolinyl)ethoxy]-  
 (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C18 H18 N2 O3  
 SR CA  
 LC STN Files: CA, CAPLUS, USPATFULL  
 DT.CA CAplus document type: Patent  
 RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 127:205585

L122 ANSWER 6 OF 8 REGISTRY COPYRIGHT 2004 ACS on STN  
 RN 194713-69-4 REGISTRY  
 CN Benzaldehyde, 4-[2-(1,4-dihydro-4-oxo-1-phenyl-3(2H)-quinazolinyl)ethoxy]-  
 (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C23 H20 N2 O3  
 SR CA  
 LC STN Files: CA, CAPLUS, USPATFULL  
 DT.CA CAplus document type: Patent  
 RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 127:205585

L122 ANSWER 7 OF 8 REGISTRY COPYRIGHT 2004 ACS on STN  
 RN 193544-83-1 REGISTRY  
 CN Benzaldehyde, 4-[(3-methyl-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)methoxy]-  
 (9CI) (CA INDEX NAME)

FS 3D CONCORD  
 MF C21 H17 N3 O2  
 SR CA  
 LC STN Files: CA, CAPLUS  
 DT.CA CAplus document type: Patent  
 RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 127:161819

L122 ANSWER 8 OF 8 REGISTRY COPYRIGHT 2004 ACS on STN  
 RN 172648-52-1 REGISTRY  
 CN Benzaldehyde, 4-[(3-methyl-3H-imidazo[4,5-b]pyridin-2-yl)methoxy]- (9CI)  
 (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C15 H13 N3 O2  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL  
 DT.CA CAplus document type: Patent  
 RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1907 TO DATE)  
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:270847

REFERENCE 2: 124:87002

=> fil hcaplus  
 FILE 'HCAPLUS' ENTERED AT 16:20:28 ON 24 AUG 2004  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Aug 2004 VOL 141 ISS 9  
FILE LAST UPDATED: 23 Aug 2004 (20040823/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all hitstr tot 1126



L126 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN  
AN 2002:793609 HCAPLUS  
DN 137:310927  
ED Entered STN: 18 Oct 2002  
TI Preparation of pyrimidinyl-amido-aryl(thio)oxy carboxylic acids as hypolipidemic agents  
IN Iqbal, Javed; Gurram, Ranga Madhavan; Das, Saibal Kumar; Bhuniya, Debnath; Chakrabarti, Ranjan; Ramanujam, Rajagopalan  
PA Reddy's Laboratories Ltd., India  
SO PCT Int. Appl., 147 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
IC ICM C07D239-36  
ICS A61K031-513; A61P003-10  
CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))  
Section cross-reference(s): 1, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002081454	A1	20021017	WO 2002-IB1104	20020408
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003013729	A1	20030116	US 2002-119300	20020408
PRAI	IN 2001-MA301	A	20010409		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002081454	ICM	C07D239-36
	ICS	A61K031-513; A61P003-10
OS	MARPAT	137:310927
GI		



AB Title compds. I [X = O, S; R1-3= H, halo, OH, NO<sub>2</sub>, CN, CHO, etc.; R3 when attached to nitrogen atom = H, OH, CHO, etc.; W = O, S, amino, C(O), OCO, etc.; m, n = 0-4; Ar= divalent single or fused aromatic or heterocyclic group; R4-5 = H, OH, alkoxy, halo, etc.; R6 = H, alkyl, cycloalkyl, etc.; Y = O, NR<sub>8</sub>; R<sub>8</sub> = H, alkyl, aryl, etc.; R<sub>6</sub>,R<sub>8</sub> together may form a (un)substituted 5-6-membered (hetero)cycle; Q= O, S, SO, SO<sub>2</sub>, etc.; p = 0-1] were prepared For instance, 2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydro-1-pyrimidinyl)acetic acid and Et 3-methyl-2-(4-heptylaminophenylthio)butanoate (preparation of starting materials given) were coupled (CH<sub>2</sub>Cl<sub>2</sub>, DIC, HOBT) to afford II. Selected example compds. at 3 mg/kg (mice) orally reduced triglycerides in mice by 36-44%. I are useful for the treatment of, e.g., obesity.

ST pyrimidine amide aryl acid prepn ppar cholesterol triglyceride obesity; hypolipidemic aryloxyacetic acid prepn

IT Antiarteriosclerotics  
(antiatherosclerotics; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPAR $\alpha$ / $\gamma$  ligands used as hypolipidemic agents)

IT Drug delivery systems  
(capsules; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPAR $\alpha$ / $\gamma$  ligands used as hypolipidemic agents)

IT Heart, disease  
(cardiac syndrome X; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPAR $\alpha$ / $\gamma$  ligands used as hypolipidemic agents)

IT Artery, disease  
(coronary; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPAR $\alpha$ / $\gamma$  ligands used as hypolipidemic agents)

IT Mental disorder  
(dementia; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPAR $\alpha$ / $\gamma$  ligands used as hypolipidemic agents)

IT Appetite  
(disorder; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPAR $\alpha$ / $\gamma$  ligands used as hypolipidemic agents)

IT Lipids, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(dyslipidemia; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPAR $\alpha$ / $\gamma$  ligands used as hypolipidemic agents)

IT Intestine, disease  
(inflammatory; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPAR $\alpha$ / $\gamma$  ligands used as hypolipidemic agents)

IT Lipoproteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(low-d.; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid  
 PPAR $\alpha/\gamma$  ligands used as hypolipidemic agents)  
 IT Muscular dystrophy  
 (myotonic; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid  
 PPAR $\alpha/\gamma$  ligands used as hypolipidemic agents)  
 IT Kidney, disease  
 (nephrosclerosis, hypertensive; pyrimidinyl-amido-aryl(thio)oxy  
 carboxylic acid PPAR $\alpha/\gamma$  ligands used as hypolipidemic  
 agents)  
 IT Pancreas, disease  
 (pancreatitis; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid  
 PPAR $\alpha/\gamma$  ligands used as hypolipidemic agents)  
 IT Ovary, disease  
 (polycystic; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid  
 PPAR $\alpha/\gamma$  ligands used as hypolipidemic agents)  
 IT Drug delivery systems  
 (powders; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid  
 PPAR $\alpha/\gamma$  ligands used as hypolipidemic agents)  
 IT Antiarteriosclerotics  
 Anticholesteremic agents  
 Antidiabetic agents  
 Antihypertensives  
 Antiobesity agents  
 Antitumor agents  
 Arteriosclerosis  
 Atherosclerosis  
 Cardiovascular system, disease  
 Diabetes insipidus  
 Diabetes mellitus  
 Human  
 Hyperglycemia  
 Hypertension  
 Hypolipemic agents  
 Kidney, disease  
 Neoplasm  
 Obesity  
 Osteoporosis  
 Psoriasis  
 (pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPAR $\alpha/\gamma$   
 ligands used as hypolipidemic agents)  
 IT Fatty acids, biological studies  
 Glycerides, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPAR $\alpha/\gamma$   
 ligands used as hypolipidemic agents)  
 IT Eye, disease  
 (retinopathy; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid  
 PPAR $\alpha/\gamma$  ligands used as hypolipidemic agents)  
 IT Drug delivery systems  
 (solns.; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid  
 PPAR $\alpha/\gamma$  ligands used as hypolipidemic agents)  
 IT Brain, disease  
 (stroke; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid  
 PPAR $\alpha/\gamma$  ligands used as hypolipidemic agents)  
 IT Drug delivery systems  
 (suspensions; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid  
 PPAR $\alpha/\gamma$  ligands used as hypolipidemic agents)  
 IT Drug delivery systems  
 (syrups; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid  
 PPAR $\alpha/\gamma$  ligands used as hypolipidemic agents)  
 IT Drug delivery systems  
 (tablets; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid  
 PPAR $\alpha/\gamma$  ligands used as hypolipidemic agents)

IT Osteoporosis  
 (therapeutic agents; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid  
 PPAR $\alpha$ / $\gamma$  ligands used as hypolipidemic agents)

IT Lipoproteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (very-low-d.; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid  
 PPAR $\alpha$ / $\gamma$  ligands used as hypolipidemic agents)

IT Skin, disease  
 (xanthoma; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid  
 PPAR $\alpha$ / $\gamma$  ligands used as hypolipidemic agents)

IT Peroxisome proliferator-activated receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 ( $\alpha$ ; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid  
 PPAR $\alpha$ / $\gamma$  ligands used as hypolipidemic agents)

IT Peroxisome proliferator-activated receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 ( $\gamma$ ; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid  
 PPAR $\alpha$ / $\gamma$  ligands used as hypolipidemic agents)

IT 59-67-6, Nicotinic acid, biological studies 11041-12-6, Cholestyramine  
 23288-49-5, Probucol 50925-79-6, Cholestipol 96829-58-2, Orlistat  
 163222-33-1, Ezetimibe  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (combination pharmaceutical; pyrimidinyl-amido-aryl(thio)oxy carboxylic  
 acid PPAR $\alpha$ / $\gamma$  ligands used as hypolipidemic agents)

IT 23501-39-5P, Ethyl 2-methyl-2-(4-nitrophenyloxy)propanoate 42806-90-6P  
 471907-17-2P 471907-18-3P 471907-19-4P 471907-20-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (intermediate; preparation of pyrimidinyl-amido-aryl(thio)oxy carboxylic  
 acids as hypolipidemic agents)

IT 471906-95-3P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic  
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
 (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of pyrimidinyl-amido-aryl(thio)oxy carboxylic acids as  
 hypolipidemic agents)

IT 471906-03-3P 471906-04-4P 471906-05-5P 471906-06-6P 471906-07-7P  
 471906-08-8P 471906-09-9P 471906-10-2P 471906-11-3P 471906-12-4P  
 471906-13-5P 471906-14-6P 471906-15-7P 471906-16-8P 471906-17-9P  
 471906-18-0P 471906-19-1P 471906-20-4P 471906-21-5P 471906-22-6P  
 471906-23-7P 471906-24-8P 471906-25-9P 471906-26-0P 471906-27-1P  
 471906-28-2P 471906-29-3P 471906-30-6P 471906-31-7P 471906-32-8P  
 471906-33-9P 471906-34-0P 471906-35-1P 471906-36-2P 471906-37-3P  
 471906-38-4P 471906-39-5P 471906-40-8P 471906-42-0P 471906-43-1P  
 471906-44-2P 471906-45-3P 471906-46-4P 471906-47-5P 471906-48-6P  
 471906-49-7P 471906-50-0P 471906-51-1P 471906-52-2P 471906-53-3P  
 471906-54-4P 471906-55-5P 471906-56-6P 471906-57-7P 471906-58-8P  
 471906-59-9P 471906-60-2P 471906-61-3P 471906-62-4P 471906-63-5P  
 471906-64-6P 471906-65-7P 471906-66-8P 471906-67-9P 471906-68-0P  
 471906-69-1P 471906-70-4P 471906-71-5P 471906-72-6P 471906-73-7P  
 471906-74-8P 471906-75-9P 471906-76-0P 471906-77-1P 471906-78-2P  
 471906-79-3P 471906-80-6P 471906-81-7P 471906-82-8P 471906-83-9P  
 471906-84-0P 471906-85-1P 471906-86-2P 471906-87-3P 471906-88-4P  
 471906-89-5P 471906-90-8P 471906-91-9P 471906-92-0P 471906-93-1P  
 471906-94-2P 471906-96-4P 471906-97-5P 471906-98-6P 471906-99-7P  
 471907-00-3P 471907-01-4P 471907-02-5P 471907-04-7P 471907-05-8P  
 471907-06-9P 471907-07-0P 471907-08-1P 471907-09-2P 471907-10-5P  
 471907-11-6P 471907-12-7P 471907-13-8P 471907-14-9P 471907-15-0P  
 471907-16-1P 471907-43-4P 471907-44-5P 471907-45-6P 471907-46-7P  
 471907-47-8P 472961-40-3P 472961-56-1P 472961-58-3P 472961-60-7P  
 472961-62-9P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

## (Uses)

(preparation of pyrimidinyl-amido-aryl(thio)oxy carboxylic acids as hypolipidemic agents)

IT 74-79-3, L-Arginine, reactions 105-36-2, Ethyl bromoacetate 123-30-8, p-Aminophenol 535-11-5, Ethyl 2-bromopropanoate 629-04-9, Heptyl bromide 637-89-8, 4-Hydroxythiophenol 5445-29-4, Ethyl 2-bromooctanoate 52421-76-8 53844-02-3, 2-Benzylloxycarbonylaminoethyl bromide 471907-40-1, 1-(2-Chloroethyl)-2-ethyl-4-phenyl-1,6-dihydropyrimidin-6-one **471907-41-2**

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrimidinyl-amido-aryl(thio)oxy carboxylic acids as hypolipidemic agents)

IT 28048-87-5P, Ethyl 2-methyl-2-(4-aminophenoxy)propanoate 287393-36-6P 471907-21-8P 471907-22-9P 471907-23-0P, Ethyl 2-(4-aminophenoxy)octanoate 471907-24-1P 471907-25-2P 471907-26-3P 471907-27-4P 471907-28-5P 471907-29-6P, Ethyl 3-methyl-2-[[4-heptylaminophenyl]sulfanyl]butanoate 471907-30-9P 471907-31-0P 471907-32-1P 471907-33-2P 471907-34-3P 471907-35-4P, 2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydro-1-pyrimidinyl)acetic acid 471907-36-5P, Ethyl 2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydro-1-pyrimidinyl)acetate 471907-37-6P, 2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydro-1-pyrimidinyl)ethylamine 471907-38-7P 471907-39-8P, 2-Ethyl-1-[2-(4-hydroxyphenylsulfanyl)ethyl]-4-phenyl-1,6-dihydropyrimidin-6-one

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrimidinyl-amido-aryl(thio)oxy carboxylic acids as hypolipidemic agents)

IT 57-88-5, Cholesterol, biological studies 9028-35-7, HMG CoA reductase RL: BSU (Biological study, unclassified); BIOL (Biological study) (pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPAR $\alpha/\gamma$  ligands used as hypolipidemic agents)

IT 100-02-7, 4-Nitrophenol, reactions 600-00-0, Ethyl 2-bromoisobutyrate RL: RCT (Reactant); RACT (Reactant or reagent) (reactant; preparation of pyrimidinyl-amido-aryl(thio)oxy carboxylic acids as hypolipidemic agents)


IT 9004-10-8, Insulin, biological studies 169494-85-3, Leptin RL: BSU (Biological study, unclassified); BIOL (Biological study) (resistance; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPAR $\alpha/\gamma$  ligands used as hypolipidemic agents)

RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD  
RE

- (1) Artico, R; BIOCHEM PHARMACOL 1968, V17(6), P893
- (2) Borck, J; US 3804839 A 1974 HCPLUS
- (3) Bordi, F; FARMACO 1989, V44(9), P795 HCPLUS
- (4) Condon, M; US 5523277 A 1996 HCPLUS
- (5) Fuji Photo Film Co Ltd; DE 3634862 A 1987 HCPLUS
- (6) Green Cross Corp; EP 0712844 A 1996 HCPLUS
- (7) Hoechst Celanese Corp; EP 0334598 A 1989 HCPLUS
- (8) Ici Plc; EP 0248554 A 1987 HCPLUS
- (9) Kuliev, A; AZERB KHIM ZH, CAPLUS Acc No 1970:12299 1969, V2, P74 HCPLUS
- (10) Liu, C; HUAXUE YANJIU YU YINGYONG, CAPLUS Acc No 1997:766522 1997, V9(5), P497 HCPLUS
- (11) Marcos, M; CHEM MATER, CAPLUS Acc No 1993:614333 1993, V5(9), P1332 HCPLUS
- (12) Nissan Chemical Ind Ltd; EP 0636615 A 1995 HCPLUS
- (13) Reddy Research Foundation; WO 9908501 A 1999 HCPLUS
- (14) Sankyo Co; EP 0587311 A 1994 HCPLUS
- (15) Schacht, E; US 3992386 A 1976 HCPLUS
- (16) Torii, Y; JP 20-00159751 A 2000 HCPLUS

IT **471907-41-2**  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of pyrimidinyl-amido-aryl(thio)oxy carboxylic acids as

hypolipidemic agents)  
 RN 471907-41-2 HCAPLUS  
 CN 4 (3H)-Pyrimidinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl-6-phenyl- (9CI)  
 (CA INDEX NAME)




L126 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1999:152363 HCAPLUS  
 DN 130:196665  
 ED Entered STN: 09 Mar 1999  
 TI Preparation of  $\omega$ -[(oxoquinazolinylalkoxy)phenyl]alkanoates and  
 analogs as PPAR $\alpha$  and PPAR $\gamma$  receptor agonists  
 IN Lohray, Vidya Hushan; Lohray, Braj Bhushan;  
 Paraselli, Rao Bheema; Ramanujam, Rajagopalan;  
 Chakrabarti, Ranjan  
 PA Reddy's Research Foundation, India; Reddy-Cheminor, Inc.  
 SO PCT Int. Appl., 140 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC C07D000-00  
 CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference(s): 1

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9908501	A2	19990225	WO 1998-US22568	19981026
	WO 9908501	A3	19990415		
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9911205	A1	19990308	AU 1999-11205	19981026
	EP 1073643	A2	20010207	EP 1998-953969	19981026
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	US 1998-82825P	P	19980423		
	WO 1998-US22568	W	19981026		

CLASS

	PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
	WO 9908501	IC	C07D000-00
OS	MARPAT	130:196665	
GI			



AB Title compds. [I; R = (CH<sub>2</sub>)<sub>n</sub>OZCHR<sub>4</sub>CR<sub>5</sub>(OR<sub>6</sub>)COYR<sub>7</sub> and R<sub>3</sub> = H, halo, alkyl, alkoxy, etc.; R = H, OH, acyl, alkyl, etc.; and R<sub>3</sub> = (CH<sub>2</sub>)<sub>n</sub>OZCHR<sub>4</sub>CR<sub>5</sub>(OR<sub>6</sub>)COYR<sub>7</sub>; R<sub>1</sub>,R<sub>2</sub> = H, halo, alkyl, alkoxy, etc.; R<sub>1</sub>R<sub>2</sub> = atoms to complete a ring; R<sub>4</sub>,R<sub>5</sub> = H, halo, alkyl, alkoxy, etc.; R<sub>4</sub>R<sub>5</sub> = bond; R<sub>6</sub> = H, acyl, alkyl aryl, etc.; R<sub>7</sub> = H, alkyl, heterocyclyl, (hetero)aryl, etc.; X = O or S; Y = O or NR<sub>8</sub>; R<sub>8</sub> = H, alkyl, aryl, etc.; R<sub>7</sub>R<sub>8</sub> = atoms to complete a ring; Z = (hetero)arylene; n = 1-4] were prepared Thus, I (R = Me, R<sub>1</sub>R<sub>2</sub> = CH:CHCH:CH, X = O) (II; R<sub>3</sub> = CH<sub>2</sub>Cl) was condensed with 4-(HO)C<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>CH(OEt)CO<sub>2</sub>Et to give II [R<sub>3</sub> = CH<sub>2</sub>OC<sub>6</sub>H<sub>4</sub>[CH<sub>2</sub>CH(OEt)CO<sub>2</sub>Et] - 4]. Data for biol. activity of I were given.

ST oxoquinazolinylalkoxyphenylalkanoate prepns PPAR alpha gamma receptor agonist; antobesity oxoquinazolinylalkoxyphenylalkanoate prepns; hypocholesteremic oxoquinazolinylalkoxyphenylalkanoate prepns

IT Anticholesteremic agents  
Antibesity agents  
(preparation of  $\omega$ -[(oxoquinazolinylalkoxy)phenyl]alkanoates and analogs as PPAR $\alpha$  and PPAR $\gamma$  receptor agonists)

IT Peroxisome proliferator-activated receptors  
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)  
( $\alpha$ , regulated functions; enhancement; preparation of  $\omega$ -[(oxoquinazolinylalkoxy)phenyl]alkanoates and analogs as PPAR $\alpha$  and PPAR $\gamma$  receptor agonists)

IT Peroxisome proliferator-activated receptors  
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)  
( $\gamma$ , regulated functions; enhancement; preparation of  $\omega$ -[(oxoquinazolinylalkoxy)phenyl]alkanoates and analogs as PPAR $\alpha$  and PPAR $\gamma$  receptor agonists)

IT 220746-16-7P 220746-17-8P 220746-18-9P 220746-19-0P 220746-20-3P  
220746-21-4P 220746-22-5P 220746-23-6P 220746-24-7P 220746-25-8P  
**220746-26-9P 220746-27-0P** 220746-28-1P 220746-29-2P  
220746-30-5P 220746-31-6P 220746-32-7P 220746-33-8P 220746-34-9P  
220746-35-0P 220746-36-1P 220746-37-2P 220746-39-4P 220746-42-9P  
220746-43-0P 220746-45-2P 220746-47-4P 220746-48-5P 220746-49-6P  
220746-50-9P 220746-51-0P 220746-52-1P 220746-53-2P 220746-54-3P  
220746-56-5P 220746-57-6P 220746-58-7P 220746-59-8P 220746-60-1P  
220746-61-2P 220746-62-3P 220746-63-4P 220746-64-5P 220746-65-6P  
220746-66-7P 220746-67-8P 220746-68-9P 220746-70-3P 220746-71-4P  
220746-72-5P 220746-73-6P 220746-74-7P 220746-75-8P 220746-76-9P  
220746-77-0P 220746-78-1P 220746-79-2P 220746-80-5P 220746-81-6P  
220746-82-7P 220746-83-8P 220746-85-0P 220746-86-1P 220746-87-2P  
220746-88-3P 220746-89-4P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of  $\omega$ -[(oxoquinazolinylalkoxy)phenyl]alkanoates and analogs as PPAR $\alpha$  and PPAR $\gamma$  receptor agonists)

IT 79-03-8, Propanoyl chloride 100-39-0, Benzyl bromide 106-94-5, Propyl bromide 109-65-9, Butyl bromide 110-91-8, Morpholine, reactions 111-83-1, Octyl bromide 118-48-9, Isatoic anhydride 348-54-9, 2-Fluoroaniline 491-36-1, 4-Quinazolinone 1769-24-0 3137-64-2 4397-53-9, 4-Benzylxybenzaldehyde 13676-06-7, Ethyl

(diethylphosphono)ethoxyacetate 16858-50-7 20989-17-7,  
 (S)-2-Phenylglycinol 22312-77-2 22312-80-7 22312-82-9 39263-96-2  
 62517-34-4 149806-75-7, 4-(2-Azidoethoxy)benzaldehyde 197299-16-4  
 199114-62-0 220746-97-4 220746-98-5 220747-00-2 220747-01-3  
 220747-02-4 220747-04-6 220747-05-7

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of  $\omega$ -[(oxoquinazolinylalkoxy)phenyl]alkanoates and  
 analogs as PPAR $\alpha$  and PPAR $\gamma$  receptor agonists)

IT 197299-09-5P 220746-90-7P 220746-91-8P 220746-92-9P 220746-93-0P  
 220746-94-1P 220746-95-2P 220746-96-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)

(preparation of  $\omega$ -[(oxoquinazolinylalkoxy)phenyl]alkanoates and  
 analogs as PPAR $\alpha$  and PPAR $\gamma$  receptor agonists)


IT 220746-26-9P 220746-27-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
 BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of  $\omega$ -[(oxoquinazolinylalkoxy)phenyl]alkanoates and  
 analogs as PPAR $\alpha$  and PPAR $\gamma$  receptor agonists)


RN 220746-26-9 HCAPLUS

CN Benzenepropanoic acid, 4-[(3,4-dihydro-3-methyl-4-oxo-2-  
 quinazolinyl)methoxy]- $\alpha$ -hydroxy-, ethyl ester (9CI) (CA INDEX NAME)



RN 220746-27-0 HCAPLUS

CN Benzenepropanoic acid, 4-[(3,4-dihydro-3-methyl-4-oxo-2-  
 quinazolinyl)methoxy]- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)



=> d all hitstr tot 1127

L127 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:264243 HCAPLUS

DN 140:270847

ED Entered STN: 01 Apr 2004

TI Preparation of antidiabetic 5-(heterocyclmethoxybenzyl)thiazolidine-2,4-

diones and their intermediates  
 IN Fujita, Takashi; Yoshioka, Takao; Fujiwara, Toshihiko; Oguchi, Minoru;  
 Yanagisawa, Hiroaki; Horikoshi, Hiroyoshi; Wada, Kunio; Fujimoto, Koichi  
 PA Sankyo Company, Limited, Japan  
 SO U.S., 87 pp., Division of U.S. 5,624,935.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 IC ICM C07D277-04  
 ICS C07D263-04  
 NCL 548183000; 548226000  
 CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference(s): 1  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5739345	A	19980414	US 1996-745377	19961108 <--
	HU 72627	A2	19960528	HU 1995-2600	19950411 <--
	US 5624935	A	19970429	US 1995-419919	19950411 <--
	IL 115269	A1	19990620	IL 1995-115269	19950912 <--
	US 5834501	A	19981110	US 1996-713543	19960913 <--
	US 5962470	A	19991005	US 1997-1093	19971230 <--
	US 5977365	A	19991102	US 1998-110693	19980707 <--
	AU 9887093	A1	19981203	AU 1998-87093	19980928 <--
	AU 712294	B2	19991104		
	US 6117893	A	20000912	US 1999-261645	19990303 <--
PRAI	JP 1994-72083	A	19940411	<--	
	US 1995-419919	A3	19950411	<--	
	IL 1995-113313	A3	19950410	<--	
	HU 1995-1040	A	19950411	<--	
	US 1996-713543	A3	19960913	<--	
	AU 1997-32443	A3	19970801		
	US 1997-1093	A3	19971230		

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 5739345	ICM	C07D277-04
	ICS	C07D263-04
	NCL	548183000; 548226000

OS MARPAT 140:270847

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [wherein X = (un)substituted indolyl, indolinyl, azaindolyl, azaindolinyl, imidazopyridyl, or imidazopyrimidinyl; Y = O or S; Z = 2,4-dioxo-thiazolidin-5-ylidenylmethyl, 2,4-dioxothiazolidin-5-ylmethyl, 2,4-dioxooxazolidin-5-ylmethyl, 3,5-dioxooxadiazolidin-2-ylmethyl or N-hydroxyureidomethyl; R = H, (ar)alkyl, alkoxy, halo, OH, NO<sub>2</sub>, or (un)substituted amino; m = 1-5; and salts thereof] were prepared as hypoglycemic and antidiabetic agents. Also disclosed are intermediate compds. II [wherein Q = alkoxycarbonyl, CHO, CO<sub>2</sub>H, or OH; Y = O or S; Y' = S; R = H, (ar)alkyl, alkoxy, halo, OH, NO<sub>2</sub>, or (un)substituted amino; m = 1-5; and salts thereof] for the preparation of I. For example, 5-chloro-2-hydroxymethyl-3-methylimidazo[5,4-b]pyridine was condensed with 5-(4-hydroxybenzyl)-3-triphenylmethylthiazolidine-2,4-dione in the presence of PBu<sub>3</sub> and 1,1'-(azodicarbonyl)dipiperidine in THF to give 5-[4-(5-chloro-3-methylimidazo[5,4-b]pyridin-2-ylmethoxy)benzyl]-3-triphenylmethylthiazolidine-2,4-dione. Deprotection using AcOH and H<sub>2</sub>O provided III, which lowered blood glucose levels in hyperglycemic male KK

mice by 37.1% at a dose of 1 mg/kg and inhibited aldose reductase activity with IC<sub>50</sub> of 1.8 μM/mL. In toxicity expts., oral administration of 50 mg/kg III to ohm male F344 rats for 2 wk produced no abnormalities and resulted in a zero mortality rate.

ST heterocyclmethoxybenzyl thiazolidinedione prepn hypoglycemic antidiabetic

IT Antidiabetic agents  
Diabetes mellitus  
Hyperglycemia  
(preparation of antidiabetic (heterocyclmethoxybenzyl)thiazolidinediones and their intermediates)

IT 50-99-7, D-Glucose, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (blood; preparation of antidiabetic (heterocyclmethoxybenzyl)thiazolidinediones and their intermediates)

IT 172647-54-0P 172647-64-2P  
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of antidiabetic (heterocyclmethoxybenzyl)thiazolidinediones and their intermediates)

IT 9028-31-3, Aldose reductase  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (preparation of antidiabetic (heterocyclmethoxybenzyl)thiazolidinediones and their intermediates)

IT 172647-48-2P 172647-49-3P 172647-50-6P 172647-51-7P 172647-52-8P  
172647-53-9P 172647-55-1P 172647-56-2P 172647-57-3P 172647-58-4P  
172647-59-5P 172647-60-8P 172647-61-9P 172647-62-0P 172647-63-1P  
172647-65-3P 172647-66-4P 172647-67-5P 172647-68-6P 172647-69-7P  
172647-70-0P 172647-71-1P 172647-72-2P 172647-73-3P 172647-74-4P  
172647-75-5P 172647-76-6P 172647-77-7P 172647-78-8P 172647-79-9P  
172647-80-2P 172647-81-3P 172647-82-4P 172647-83-5P 172647-84-6P  
172647-85-7P 172647-86-8P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of antidiabetic (heterocyclmethoxybenzyl)thiazolidinediones and their intermediates)

IT 54-96-6, 4,5-Diaminopyridine 96-32-2, Methyl bromoacetate 96-48-0, γ-Butyrolactone 100-02-7, reactions 100-51-6, Benzenemethanol, reactions 104-86-9, 4-Chlorobenzylamine 108-98-5, Thiophenol, reactions 120-72-9, Indole, reactions 123-08-0, 4-Hydroxybenzaldehyde 141-32-2 271-63-6, 7-Azaindole 452-58-4, 2,3-Diaminopyridine 504-29-0, 2-Aminopyridine 623-50-7, Ethyl glycolate 637-81-0, Ethyl azidoacetate 638-07-3, Ethyl 4-chloroacetoacetate 1072-97-5, 2-Amino-5-bromopyridine 1072-98-6, 2-Amino-5-chloropyridine 1667-11-4, 4-(Chloromethyl)biphenyl 2032-35-1, Bromoacetaldehyde diethyl acetal 5470-18-8, 2-Chloro-3-nitropyridine 6332-56-5, 2-Hydroxy-3-nitropyridine 6602-54-6, 2-Chloro-3-cyanopyridine 16013-85-7, 2,6-Dichloro-3-nitropyridine 24638-20-8, 1H-Imidazo[4,5-b]pyridine-2-methanol 27048-04-0 38922-77-9, Ethyl imidazo[1,2-a]pyridine-2-carboxylate 74772-78-4 78348-24-0, Indoline-2-carboxylic acid 92381-62-9, 1H-Imidazo[4,5-c]pyridine-2-methanol 115951-72-9 150556-72-2 172648-54-3 172648-55-4  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of antidiabetic (heterocyclmethoxybenzyl)thiazolidinediones and their intermediates)

IT 591-81-1P, 4-Hydroxybutyric acid 1485-22-9P 3723-71-5P 4093-88-3P, 2-Methylamino-3-nitropyridine 5028-20-6P 5409-39-2P 6642-26-8P, 1H-Purine-8-methanol 6945-68-2P, 2-Amino-5-bromo-3-nitropyridine 19786-48-2P 21755-34-0P 21755-54-4P, Imidazo[1,2-a]pyridine-2-ethanol 25710-20-7P, 5-Chloro-2,3-diaminopyridine 32282-18-1P 32329-12-7P 33140-80-6P 33742-70-0P 34949-41-2P 36404-88-3P,

2-Chloro-3-formylpyridine 37493-34-8P 38875-53-5P,  
 5-Bromo-2,3-diaminopyridine 39597-68-7P 40851-95-4P,  
 6-Chloro-2,3-diaminopyridine 41010-49-5P 42048-25-9P 50501-07-0P,  
 Ethyl indoline-2-carboxylate 59954-04-0P, Methyl 4-aminophenoxyacetate  
 76182-48-4P 82090-52-6P, Imidazo[1,2-a]pyridine-2-methanol 90817-34-8P  
 90874-78-5P 90929-77-4P, 1H-Pyrrolo[2,3-b]pyridine-1-ethanol  
 91371-83-4P 94166-58-2P 121459-15-2P, 1H-Indole-1-ethanol  
 138969-57-0P 148433-49-2P 164224-08-2P 172647-87-9P 172647-88-0P  
 172647-89-1P 172647-90-4P 172647-91-5P 172647-92-6P 172647-93-7P  
 172647-94-8P 172647-95-9P 172647-96-0P 172647-97-1P 172647-98-2P  
 172647-99-3P 172648-00-9P 172648-01-0P 172648-02-1P,  
 1H-Imidazo[4,5-b]pyridine-2-propanol 172648-03-2P 172648-04-3P  
 172648-05-4P 172648-06-5P 172648-07-6P 172648-08-7P 172648-09-8P  
 172648-10-1P 172648-11-2P 172648-12-3P 172648-13-4P 172648-14-5P  
 172648-15-6P 172648-16-7P 172648-17-8P 172648-18-9P 172648-19-0P  
 172648-20-3P 172648-21-4P 172648-22-5P 172648-23-6P 172648-24-7P  
 172648-25-8P 172648-26-9P 172648-27-0P 172648-28-1P 172648-29-2P  
 172648-30-5P 172648-31-6P 172648-32-7P 172648-33-8P 172648-34-9P  
 172648-35-0P 172648-36-1P 172648-37-2P 172648-38-3P 172648-39-4P  
 172648-40-7P 172648-41-8P 172648-42-9P 172648-43-0P 172648-44-1P  
 172648-45-2P 172648-46-3P 172648-47-4P 172648-48-5P 172648-49-6P  
 172648-50-9P 172648-51-0P **172648-52-1P** 172648-53-2P  
 172648-56-5P 172648-57-6P 172648-58-7P 172648-59-8P 172648-60-1P  
 172648-61-2P 172648-62-3P 172648-63-4P 298231-55-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of antidiabetic (heterocyclmethoxybenzyl)thiazolidinediones and their intermediates)

RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD  
RE

- (1) Anon; JP 53-1217758 1978
- (2) Anon; EP 0008203 1980 HCPLUS
- (3) Anon; EP 0139421 1985 HCPLUS
- (4) Anon; EP 0177353 1986 HCPLUS
- (5) Anon; EP 0208420 1987 HCPLUS
- (6) Anon; EP 0306228 1989 HCPLUS
- (7) Anon; EP 0356214 1990 HCPLUS
- (8) Anon; EP 0441605 1991 HCPLUS
- (9) Anon; WO 9107107 1991 HCPLUS
- (10) Anon; WO 9202520 1992 HCPLUS
- (11) Anon; WO 9203425 1992 HCPLUS
- (12) Anon; WO 9207839 1992 HCPLUS
- (13) Anon; WO 9207850 1992 HCPLUS
- (14) Anon; EP 0528734 1993 HCPLUS
- (15) Austin, P; The Ring Index-2nd Edition 1960, P157
- (16) Hindley; US 5075300 1991 HCPLUS
- (17) Takebayashi; US 5387596 1995 HCPLUS
- (18) Yoshioka; US 4572912 1986 HCPLUS
- (19) Yoshioka; US 4691027 1987 HCPLUS
- (20) Yoshioka; US 4871762 1989 HCPLUS
- (21) Yoshioka; US 4873255 1989 HCPLUS
- (22) Yoshioka; US 5104888 1992 HCPLUS
- (23) Yoshioka; US 5143930 1992 HCPLUS
- (24) Yoshioka; US 5338855 1994 HCPLUS


IT **172648-52-1P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of antidiabetic (heterocyclmethoxybenzyl)thiazolidinediones and their intermediates)

RN 172648-52-1 HCPLUS

CN Benzaldehyde, 4-[(3-methyl-3H-imidazo[4,5-b]pyridin-2-yl)methoxy] - (9CI)  
(CA INDEX NAME)



L127 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 1997:553183 HCAPLUS

DN 127:205585

ED Entered STN: 30 Aug 1997

TI Preparation of benzoazines for reducing blood glucose level

IN Nagao, Yoshihiro; Ito, Yoshikuni; Kotake, Jiro; Kouda, Tadayuki; Honda, Haruyoshi; Sato, Susumu; Matsuda, Hideaki

PA SS Pharmaceutical Co., Ltd., Japan

SO Eur. Pat. Appl., 21 pp.

CODEN: EPXXDW

DT Patent

LA English

IC ICM C07D417-12

ICS A61K031-425; A61K031-505

CC 28-13 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

FAN.CNT 1



	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 787727	A1	19970806	EP 1997-101626	19970131 <--
	R: BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
	TW 399051	B	20000721	TW 1997-86100906	19970128 <--
	JP 09268189	A2	19971014	JP 1997-15135	19970129 <--
	CA 2196400	AA	19970801	CA 1997-2196400	19970130 <--
	US 5710152	A	19980120	US 1997-791269	19970130 <--
	CN 1167764	A	19971217	CN 1997-101300	19970131 <--
PRAI	JP 1996-14898	A	19960131 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
EP 787727	ICM	C07D417-12
	ICS	A61K031-425; A61K031-505

OS MARPAT 127:205585

GI



AB The title compds. [I; R1 = alkyl, alkoxy, halo, etc.; R2, R3 = H, alkyl; R2R3 = C2-7 alkylene; R4, R5 = H, alkyl; X = O, S, NR6 (wherein R6 = H, alkyl, aryl, pyridyl); m = 0-4; n = 1-3] which exhibit superior effects for reducing blood glucose value, plasma insulin value, and plasma triglyceride value, and are useful as a medicament for preventing or treating diabetes, hyperlipidemia, and obesity, were prepared. Thus, reaction of 4-[2-(4-oxo-3,4-dihydro-2H-1,3-benzoxazin-3-yl)ethoxy]benzaldehyde with 2,4-thiazolidinedione in the presence of a catalytic amount of AcOH and piperidine in PhMe followed by hydrogenation of the resulting thiazolidinedione II over 10% Pd/C in 1,4-dioxane afforded I [R1-R5 = H; X = O; n = 1] which showed 65.8% blood glucose reduction at 9.8 mg/kg/day.

ST benzoazine prepn blood glucose level redn; antidiabetic benzoazine prepn; hypolipemic benzoazine prepn; antiobesity agent benzoazine prepn

IT Antidiabetic agents

Antiobesity agents

Hypolipemic agents

(preparation of benzoazines for reducing blood glucose level)

IT 194713-46-7P 194713-48-9P 194713-49-0P 194713-50-3P 194713-51-4P  
 194713-52-5P 194713-53-6P 194713-54-7P 194713-55-8P 194713-56-9P  
 194713-57-0P 194713-58-1P 194713-59-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzoazines for reducing blood glucose level)

IT 65-45-2, Salicylamide 77-76-9, Acetone dimethylacetal 459-57-4,  
 p-Fluorobenzaldehyde 534-15-6, Acetaldehyde dimethylacetal 2295-31-0,  
 2,4-Thiazolidinedione 142558-08-5 143248-47-9 143248-50-4  
 143248-51-5 143248-73-1 159691-53-9 159691-57-3 159691-58-4  
 159691-59-5 194713-82-1 194713-83-2 194713-84-3 194713-85-4  
 194713-86-5 194713-87-6 194713-88-7 194713-89-8 194713-90-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of benzoazines for reducing blood glucose level)

IT 30914-88-6P 194713-60-5P 194713-61-6P 194713-62-7P 194713-63-8P  
 194713-64-9P 194713-65-0P 194713-66-1P 194713-67-2P 194713-68-3P  
**194713-69-4P 194713-70-7P 194713-71-8P**

194713-72-9P 194713-73-0P 194713-74-1P 194713-75-2P 194713-76-3P

194713-77-4P 194713-78-5P 194713-79-6P 194713-80-9P 194713-81-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzoazines for reducing blood glucose level)


IT **194713-69-4P 194713-70-7P 194713-71-8P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzoazines for reducing blood glucose level)


RN 194713-69-4 HCPLUS

CN Benzaldehyde, 4-[2-(1,4-dihydro-4-oxo-1-phenyl-3(2H)-quinazolinyl)ethoxy] - (9CI) (CA INDEX NAME)




RN 194713-70-7 HCPLUS

CN Benzaldehyde, 4-[2-(1,4-dihydro-1-methyl-4-oxo-3(2H)-quinazolinyl)ethoxy] - (9CI) (CA INDEX NAME)



RN 194713-71-8 HCPLUS

CN Benzaldehyde, 4-[2-[1,4-dihydro-4-oxo-1-(2-pyridinyl)-3(2H)-quinazolinyl]ethoxy] - (9CI) (CA INDEX NAME)



L127 ANSWER 3 OF 4 HCPLUS COPYRIGHT 2004 ACS on STN

AN 1997:483428 HCPLUS

DN 127:161819

ED Entered STN: 04 Aug 1997

TI Preparation and formulation of thiazolidinediones as pharmaceuticals

IN Fujita, Takeshi; Oguchi, Minoru; Wada, Kunio; Fujimoto, Koichi; Yanagisawa, Hiroaki; Fujiwara, Toshihiko; Horikoshi, Hiroyoshi; Yoshioka, Takao

PA Sankyo Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 171 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

IC ICM C07D209-08

ICS A61K031-40; A61K031-41; A61K031-42; A61K031-425; A61K031-435;  
 C07D209-10; C07D209-12; C07D209-36; C07D413-12; C07D417-12;  
 C07D471-04; C07D487-04; C07D263-14; C07D271-06; C07D209-08;  
 C07D277-34

CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference(s): 1, 63



FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 09165371	A2	19970624	JP 1996-265978	19961007 <--
PRAI JP 1995-261545		19951009	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
JP 09165371	ICM	C07D209-08
	ICS	A61K031-40; A61K031-41; A61K031-42; A61K031-425; A61K031-435; C07D209-10; C07D209-12; C07D209-36; C07D413-12; C07D417-12; C07D471-04; C07D487-04; C07D263-14; C07D271-06; C07D209-08; C07D277-34

OS MARPAT 127:161819  
 GI



AB The title compds. I [X = indole ring, etc.; Y = O, etc.; Z = thiazolidine-2,4-dione-5-ylmethyl, etc.; R = H, etc.; m = 1 - 5] are prepared. The title compound II at 10 mg/kg orally gave 13.2% decrease in blood sugar in diabetic mice.

ST thiazolidinedione prepn pharmaceutical; antidiabetic thiazolidinedione prepn

IT Antidiabetic agents

Antihypertensives

Hypolipemic agents

(thiazolidinediones)

IT 172647-48-2P	172647-50-6P	172647-51-7P	172647-52-8P	172647-53-9P
172647-54-0P	172647-55-1P	172647-56-2P	172647-57-3P	172647-58-4P
172647-59-5P	172647-60-8P	172647-61-9P	172647-62-0P	172647-63-1P
172647-64-2P	172647-65-3P	172647-66-4P	172647-67-5P	172647-68-6P
172647-69-7P	172647-70-0P	172647-71-1P	172647-74-4P	172647-75-5P
172647-76-6P	172647-77-7P	172647-79-9P	172647-80-2P	172647-81-3P

172647-82-4P 172647-83-5P 172647-84-6P 172647-85-7P 172647-86-8P  
 193544-58-0P 193544-59-1P 193544-60-4P 193544-61-5P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of thiazolidinediones as pharmaceuticals)

IT 54-96-6, 4,5-Diaminopyridine 62-53-3, Benzenamine, reactions 62-56-6, Thiourea, reactions 74-88-4, Methyl iodide, reactions 79-14-1, Glycolic acid, reactions 96-32-2, Methyl bromoacetate 96-48-0,  $\gamma$ -Butyrolactone 98-80-6, Phenylboronic acid 100-02-7, reactions 100-51-6, Benzyl alcohol, reactions 104-86-9, 4-Chlorobenzylamine 120-72-9, Indole, reactions 123-08-0 271-63-6, 7-Azaindole 452-58-4, 2,3-Diaminopyridine 496-15-1, Indoline 504-29-0, 2-Aminopyridine 526-55-6, 2-(Indol-3-yl)ethanol 623-50-7, Ethyl glycolate 638-07-3, Ethyl 4-chloroacetoacetate 1072-97-5, 2-Amino-5-bromopyridine 1667-11-4, 4-(Chloromethyl)biphenyl 2295-31-0, 2,4-Thiazolidinedione 5470-18-8, 2-Chloro-3-nitropyridine 6332-56-5, 2-Hydroxy-3-nitropyridine 6602-54-6, 2-Chloro-3-cyanopyridine 16013-85-7, 2,6-Dichloro-3-nitropyridine 18162-48-6, tert-Butyldimethylsilyl chloride 18742-02-4, 2-(2-Bromoethyl)-1,3-dioxolane 24424-99-5, Di-tert-butyl-di-carbonate 24638-20-8, 1H-Imidazo[4,5-b]pyridine-2-methanol 27048-04-0 38922-77-9, Ethyl imidazo[1,2-a]pyridine-2-carboxylate 50850-16-3, 2,3-Diamino-4,6-dimethylpyridine 74772-78-4 78348-24-0, Indoline-2-carboxylic acid 92381-62-9, 1H-Imidazo[4,5-c]pyridine-2-methanol 115951-72-9 150556-72-2 172648-55-4  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of thiazolidinediones as pharmaceuticals)


IT 591-81-1P 1485-22-9P 4093-88-3P 5028-20-6P 5409-39-2P  
 6642-26-8P, 1H-Purine-8-methanol 6945-68-2P 19786-48-2P 21755-34-0P  
 21755-54-4P, Imidazo[1,2-a]pyridine-2-ethanol 25710-20-7P 32329-12-7P  
 33140-80-6P 33742-70-0P 34949-41-2P 36404-88-3P 37493-34-8P  
 38875-53-5P 40851-95-4P 41010-49-5P 50501-07-0P 59954-04-0P  
 76182-48-4P 82090-52-6P, Imidazo[1,2-a]pyridine-2-methanol 90817-34-8P  
 90874-78-5P 90929-77-4P, 1H-Pyrrolo[2,3-b]pyridine-1-ethanol  
 91371-83-4P 94166-58-2P 121459-15-2P, 1H-Indole-1-ethanol  
 138969-57-0P 148433-49-2P 164224-08-2P 172647-87-9P 172647-88-0P  
 172647-89-1P 172647-90-4P 172647-91-5P 172647-92-6P 172647-94-8P  
 172647-95-9P 172647-96-0P 172647-97-1P 172647-98-2P 172648-00-9P  
 172648-01-0P 172648-02-1P, 1H-Imidazo[4,5-b]pyridine-2-propanol  
 172648-05-4P 172648-06-5P 172648-07-6P 172648-08-7P 172648-09-8P  
 172648-10-1P 172648-11-2P 172648-12-3P 172648-13-4P 172648-14-5P  
 172648-17-8P 172648-18-9P 172648-19-0P 172648-20-3P 172648-21-4P  
 172648-22-5P 172648-23-6P 172648-24-7P 172648-25-8P 172648-26-9P  
 172648-27-0P 172648-28-1P 172648-29-2P 172648-30-5P 172648-31-6P  
 172648-32-7P 172648-33-8P 172648-34-9P 172648-35-0P 172648-36-1P  
 172648-37-2P 172648-38-3P 172648-39-4P 172648-40-7P 172648-41-8P  
 172648-42-9P 172648-43-0P 172648-44-1P 172648-45-2P 172648-48-5P  
 172648-49-6P 172648-50-9P 172648-51-0P 172648-53-2P 172648-56-5P  
 172648-57-6P 172648-58-7P 172648-61-2P 172648-62-3P 172648-63-4P  
 193544-62-6P 193544-67-1P 193544-72-8P 193544-73-9P 193544-74-0P  
 193544-75-1P 193544-76-2P 193544-77-3P 193544-78-4P 193544-79-5P  
 193544-80-8P 193544-81-9P 193544-82-0P **193544-83-1P**  
 193546-71-3P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of thiazolidinediones as pharmaceuticals)

IT **193544-83-1P**  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of thiazolidinediones as pharmaceuticals)

RN 193544-83-1 HCPLUS



CN Benzaldehyde, 4-[(3-methyl-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)methoxy]-(9CI) (CA INDEX NAME)



L127 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN  
AN 1995:994680 HCAPLUS  
DN 124:87002  
ED Entered STN: 22 Dec 1995  
TI Preparation of benzylthiazolidinediones and related compounds having  
antidiabetic activity.  
IN Fujita, Takashi; Fujimoto, Koichi; Yoshioka, Takao; Yanagisawa, Hiroaki;  
Fujiwara, Toshihiko; Horikoshi, Hiroyoshi; Oguchi, Minoru; Wada, Kunio  
PA Sankyo Co., Ltd., Japan  
SO Eur. Pat. Appl., 166 pp.  
CODEN: EPXXDW  
DT Patent  
LA English  
IC ICM C07D417-10  
ICS C07D413-10; C07D471-04; A61K031-49; A61K031-425  
CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))  
Section cross-reference(s): 1

PATENT NO.		KIND	DATE	APPLICATION NO.	DATE
PI	EP 676398	A2	19951011	EP 1995-302409	19950411 <--
	EP 676398	A3	19980701		
	EP 676398	B1	20011024		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CA 2146701	AA	19951012	CA 1995-2146701	19950410 <--
	NO 9501398	A	19951012	NO 1995-1398	19950410 <--
	RU 2114844	C1	19980710	RU 1995-105423	19950410 <--
	IL 113313	A1	19990922	IL 1995-113313	19950410 <--
	RU 2151145	C1	20000620	RU 1995-118736	19950410 <--
	CZ 289317	B6	20020116	CZ 1995-910	19950410 <--
	FI 9501731	A	19951012	FI 1995-1731	19950411 <--
	AU 9516383	A1	19951019	AU 1995-16383	19950411 <--
	AU 683348	B2	19971106		
	JP 07330728	A2	19951219	JP 1995-85161	19950411 <--
	ZA 9502990	A	19951221	ZA 1995-2990	19950411 <--
	CN 1118781	A	19960320	CN 1995-105765	19950411 <--
	CN 1060173	B	20010103		
	HU 72627	A2	19960528	HU 1995-2600	19950411 <--
	HU 73765	A2	19960930	HU 1995-1040	19950411 <--
	HU 219887	B	20010828		
	EP 1022274	A1	20000726	EP 2000-102313	19950411 <--
	EP 1022274	B1	20020828		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
	TW 407156	B	20001001	TW 1995-84103469	19950411 <--
	AT 207488	E	20011115	AT 1995-302409	19950411 <--
	PT 676398	T	20020328	PT 1995-302409	19950411 <--
	ES 2165895	T3	20020401	ES 1995-302409	19950411 <--
	AT 222895	E	20020915	AT 2000-102313	19950411 <--
	TW 503237	B	20020921	TW 1998-87114283	19950411 <--
	PT 1022274	T	20021129	PT 2000-102313	19950411 <--
	ES 2180477	T3	20030216	ES 2000-102313	19950411 <--
	IL 115269	A1	19990620	IL 1995-115269	19950912 <--

AU 9732443	A1	19971023	AU 1997-32443	19970801 <--
AU 700354	B2	19990107		
US 5962470	A	19991005	US 1997-1093	19971230 <--
US 5977365	A	19991102	US 1998-110693	19980707 <--
NO 9803900	A	19951012	NO 1998-3900	19980825 <--
AU 9887093	A1	19981203	AU 1998-87093	19980928 <--
AU 712294	B2	19991104		
HK 1011365	A1	20020816	HK 1998-112512	19981130 <--
HK 1029338	A1	20030103	HK 2000-108123	19981130 <--
US 6117893	A	20000912	US 1999-261645	19990303 <--
PRAI JP 1994-72083	A	19940411	<--	
IL 1995-113313	A3	19950410	<--	
EP 1995-302409	A3	19950411	<--	
HU 1995-1040	A	19950411	<--	
US 1995-419919	A3	19950411	<--	
US 1996-713543	A3	19960913	<--	
AU 1997-32443	A3	19970801		
US 1997-1093	A3	19971230		
CLASS				
PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES		
-----	-----	-----		
EP 676398	ICM	C07D417-10		
	ICS	C07D413-10; C07D471-04; A61K031-49; A61K031-425		
OS MARPAT 124:87002				
GI				



AB Title compds. [I; X = (substituted) indolyl, indolinyl, azaindolyl, azaindolinyl, imidazopyridyl, imidazopyrimidinyl; Y = O, S; Z = Q1, Q2, CH2N(OH)CONH2, etc.; R = H, alkyl, alkoxy, halo, OH, NO2, aralkyl, (substituted) amino; m= 1-5], were prepared Thus, 5-[4-(5-chloro-3-methylimidazo[5,4-b]pyridin-2-ylmethoxy)benzyl]-thiazolidine-2,4-dione (preparation via cyclocondensation of glycolic acid with 6-chloro-2,3-diaminopyridine given) at 1 mg/kg orally in mice showed 37.1% hypoglycemic effect.

ST benzylthiazolidinedione prepn antidiabetic; thiazolidinedione benzyl prepn antidiabetic

IT Antidiabetics and Hypoglycemics  
(preparation of benzylthiazolidinediones and related compds. having antidiabetic activity)

IT 172648-35-0P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(benzylthiazolidinediones and related compds. having antidiabetic activity)

IT 172647-48-2P 172647-49-3P 172647-50-6P 172647-51-7P 172647-52-8P  
 172647-53-9P 172647-54-0P 172647-55-1P 172647-56-2P 172647-57-3P  
 172647-58-4P 172647-59-5P 172647-60-8P 172647-61-9P 172647-62-0P  
 172647-63-1P 172647-64-2P 172647-65-3P 172647-66-4P 172647-67-5P  
 172647-68-6P 172647-69-7P 172647-70-0P 172647-71-1P 172647-72-2P  
 172647-73-3P 172647-74-4P 172647-75-5P 172647-76-6P 172647-77-7P  
 172647-78-8P 172647-79-9P 172647-80-2P 172647-81-3P 172647-82-4P  
 172647-83-5P 172647-84-6P 172647-85-7P 172647-86-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzylthiazolidinediones and related compds. having antidiabetic activity)

IT 54-96-6, 4,5-Diaminopyridine 62-56-6, Thiourea, reactions 67-63-0, Isopropanol, reactions 74-88-4, Methyl iodide, reactions 74-89-5, Methanamine, reactions 75-03-6, Ethyl iodide 79-14-1, reactions 96-32-2, Methyl bromoacetate 96-48-0,  $\gamma$ -Butyrolactone 100-02-7, reactions 100-51-6, Benzenemethanol, reactions 104-86-9, 4-Chlorobenzylamine 108-98-5, Thiophenol, reactions 120-72-9, Indole, reactions 123-08-0, 4-Hydroxybenzaldehyde 141-32-2 271-63-6, 7-Azaindole 452-58-4, 2,3-Diaminopyridine 504-29-0, 2-Aminopyridine 623-50-7, Ethyl glycolate 637-81-0, Ethyl azidoacetate 638-07-3, Ethyl 4-chloroacetoacetate 1072-97-5, 2-Amino-5-bromopyridine 1072-98-6, 2-Amino-5-chloropyridine 1667-11-4, 4-(Chloromethyl)biphenyl 2032-35-1, Bromoacetaldehyde diethyl acetal 5470-18-8, 2-Chloro-3-nitropyridine 6332-56-5, 2-Hydroxy-3-nitropyridine 6602-54-6, 2-Chloro-3-cyanopyridine 16013-85-7, 2,6-Dichloro-3-nitropyridine 24638-20-8, 1H-Imidazo[4,5-b]pyridine-2-methanol 27048-04-0 38922-77-9, Ethyl imidazo[1,2-a]pyridine-2-carboxylate 74772-78-4 78348-24-0, Indoline-2-carboxylic acid 92381-62-9, 1H-Imidazo[4,5-c]pyridine-2-methanol 115951-72-9 150556-72-2 172648-54-3 172648-55-4

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of benzylthiazolidinediones and related compds. having antidiabetic activity)

IT 591-81-1P, 4-Hydroxybutyric acid 1485-22-9P 3723-71-5P 4093-88-3P, 2-Methylamino-3-nitropyridine 5028-20-6P 5409-39-2P 6642-26-8P, 1H-Purine-8-methanol 6945-68-2P, 2-Amino-5-bromo-3-nitropyridine 19786-48-2P 21755-34-0P 21755-54-4P, Imidazo[1,2-a]pyridine-2-ethanol 25710-20-7P, 5-Chloro-2,3-diaminopyridine 32282-18-1P 32329-12-7P 33140-80-6P 33742-70-0P 34949-41-2P 36404-88-3P, 2-Chloro-3-formylpyridine 37493-34-8P 38875-53-5P, 5-Bromo-2,3-diaminopyridine 39597-68-7P 40851-95-4P, 6-Chloro-2,3-diaminopyridine 41010-49-5P 42048-25-9P 50501-07-0P, Ethyl indoline-2-carboxylate 59954-04-0P, Methyl 4-aminophenoxyacetate 76182-48-4P 82090-52-6P, Imidazo[1,2-a]pyridine-2-methanol 90817-34-8P 90874-78-5P 90929-77-4P, 1H-Pyrrolo[2,3-b]pyridine-1-ethanol 91371-83-4P 94166-58-2P 121459-15-2P, 1H-Indole-1-ethanol 138969-57-0P 148433-49-2P 164224-08-2P 172647-87-9P 172647-88-0P 172647-89-1P 172647-90-4P 172647-91-5P 172647-92-6P 172647-93-7P 172647-94-8P 172647-95-9P 172647-96-0P 172647-97-1P 172647-98-2P 172647-99-3P 172648-00-9P 172648-01-0P 172648-02-1P, 1H-Imidazo[4,5-b]pyridine-2-propanol 172648-03-2P 172648-04-3P 172648-05-4P 172648-06-5P 172648-07-6P 172648-08-7P 172648-09-8P 172648-10-1P 172648-11-2P 172648-12-3P 172648-13-4P 172648-14-5P 172648-15-6P 172648-16-7P 172648-17-8P 172648-18-9P 172648-19-0P 172648-20-3P 172648-21-4P 172648-22-5P 172648-23-6P 172648-24-7P 172648-25-8P 172648-26-9P 172648-27-0P 172648-28-1P 172648-29-2P 172648-30-5P 172648-31-6P 172648-32-7P 172648-33-8P 172648-34-9P 172648-36-1P 172648-37-2P 172648-38-3P 172648-39-4P 172648-40-7P 172648-41-8P 172648-42-9P 172648-43-0P 172648-44-1P 172648-45-2P

172648-46-3P 172648-47-4P 172648-48-5P 172648-49-6P 172648-50-9P  
 172648-51-0P **172648-52-1P** 172648-53-2P 172648-56-5P  
 172648-57-6P 172648-58-7P 172648-59-8P 172648-60-1P 172648-61-2P  
 172648-62-3P 172648-63-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzylthiazolidinediones and related compds. having antidiabetic activity)


IT **172648-52-1P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzylthiazolidinediones and related compds. having antidiabetic activity)

RN 172648-52-1 HCPLUS

CN Benzaldehyde, 4-[(3-methyl-3H-imidazo[4,5-b]pyridin-2-yl)methoxy]- (9CI)  
 (CA INDEX NAME)



=>

=> fil reg  
FILE 'REGISTRY' ENTERED AT 15:05:28 ON 24 AUG 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 23 AUG 2004 HIGHEST RN 731771-88-3  
DICTIONARY FILE UPDATES: 23 AUG 2004 HIGHEST RN 731771-88-3

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004


Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more  
information enter HELP PROP at an arrow prompt in the file or refer  
to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d 153 ide can tot

L53 ANSWER 1 OF 20 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 199114-57-3 REGISTRY  
CN Benzene propanoic acid,  $\alpha$ -bromo-4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C22 H23 Br N2 O4  
SR CA  
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL  
DT.CA CAplus document type: Patent  
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

3 REFERENCES IN FILE CA (1907 TO DATE)  
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:331438

REFERENCE 2: 131:351343

REFERENCE 3: 128:13282


L53 ANSWER 2 OF 20 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 199114-56-2 REGISTRY  
CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-methyl- (9CI) (CA

## INDEX NAME)

FS 3D CONCORD  
 MF C17 H17 N3 O2  
 SR CA

LC STN Files: CA, CAPLUS, USPAT2, USPATFULL  
 DT.CA CAplus document type: Patent

RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

3 REFERENCES IN FILE CA (1907 TO DATE)  
 3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:331438

REFERENCE 2: 131:351343

REFERENCE 3: 128:13282

L53 ANSWER 3 OF 20 REGISTRY COPYRIGHT 2004 ACS on STN

RN 199114-54-0 REGISTRY

CN Benzaldehyde, 4-[(2-(2,5,6-trimethyl-4-oxothieno[2,3-d]pyrimidin-3(4H)-yl)ethoxy)- (9CI) (CA INDEX NAME)

FS 3D CONCORD


MF C18 H18 N2 O3 S

SR CA

LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

DT.CA CAplus document type: Patent

RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1907 TO DATE)  
 4 REFERENCES IN FILE CAPLUS (1907 TO DATE)


REFERENCE 1: 135:331438

REFERENCE 2: 131:351343

REFERENCE 3: 130:223293

REFERENCE 4: 128:13282

L53 ANSWER 4 OF 20 REGISTRY COPYRIGHT 2004 ACS on STN  
 RN 199114-52-8 REGISTRY  
 CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]- $\alpha$ -hydroxy-, ethyl ester (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C20 H26 N2 O5  
 SR CA  
 LC STN Files: CA, CAPLUS, USPAT2, USPATFULL  
 DT.CA CAplus document type: Patent  
 RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)




6

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1907 TO DATE)  
 4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:331438  
 REFERENCE 2: 131:351343  
 REFERENCE 3: 130:223293  
 REFERENCE 4: 128:13282

L53 ANSWER 5 OF 20 REGISTRY COPYRIGHT 2004 ACS on STN  
 RN 199114-51-7 REGISTRY  
 CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C18 H22 N2 O5  
 SR CA  
 LC STN Files: CA, CAPLUS, USPAT2, USPATFULL  
 DT.CA CAplus document type: Patent  
 RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



7 5

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1907 TO DATE)  
 4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:331438  
 REFERENCE 2: 131:351343

REFERENCE 3: 130:223293

REFERENCE 4: 128:13282

L53 ANSWER 6 OF 20 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 199114-48-2 REGISTRYCN Benzenepropanoic acid,  $\alpha$ -bromo-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)

FS 3D CONCORD


MF C23 H25 Br N2 O4

SR CA

LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

DT.CA CAplus document type: Patent

RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1907 TO DATE)

4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:331438

REFERENCE 2: 131:351343

REFERENCE 3: 130:223293

REFERENCE 4: 128:13282

L53 ANSWER 7 OF 20 REGISTRY COPYRIGHT 2004 ACS on STN

RN 199114-47-1 REGISTRY

CN Benzenepropanoic acid,  $\alpha$ -bromo-4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)

FS 3D CONCORD


MF C20 H25 Br N2 O4

SR CA

LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

DT.CA CAplus document type: Patent

RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1907 TO DATE)  
 4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:331438

REFERENCE 2: 131:351343

REFERENCE 3: 130:223293

REFERENCE 4: 128:13282

L53 ANSWER 8 OF 20 REGISTRY COPYRIGHT 2004 ACS on STN  
 RN 199114-46-0 REGISTRY

CN 4 (3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl- (9CI) (CA INDEX NAME)

FS 3D CONCORD


MF C18 H19 N3 O2

SR CA

LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

DT.CA CAplus document type: Patent

RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



(H) 2

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1907 TO DATE)  
 4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:331438

REFERENCE 2: 131:351343

REFERENCE 3: 130:223293

REFERENCE 4: 128:13282

L53 ANSWER 9 OF 20 REGISTRY COPYRIGHT 2004 ACS on STN  
 RN 199114-45-9 REGISTRY

CN 4 (3H)-Pyrimidinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl-6-methyl- (9CI) (CA INDEX NAME)

FS 3D CONCORD


MF C15 H19 N3 O2

SR CA

LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

DT.CA CAplus document type: Patent

RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1907 TO DATE)  
 4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:331438

REFERENCE 2: 131:351343

REFERENCE 3: 130:223293

REFERENCE 4: 128:13282

L53 ANSWER 10 OF 20 REGISTRY COPYRIGHT 2004 ACS on STN  
 RN 199114-42-6 REGISTRY

CN Urea, N-[[4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]phenyl]methyl]-N-hydroxy- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C17 H22 N4 O4


SR CA

LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPAT2, USPATFULL

DT.CA CAplus document type: Journal; Patent

RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)

RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

5 REFERENCES IN FILE CA (1907 TO DATE)  
 5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 138:82897

REFERENCE 2: 135:331438

REFERENCE 3: 131:351343

REFERENCE 4: 130:223293


REFERENCE 5: 128:13282

L53 ANSWER 11 OF 20 REGISTRY COPYRIGHT 2004 ACS on STN

RN 199114-41-5 REGISTRY

CN 4(3H)-Pyrimidinone, 2-ethyl-3-[2-[4-[(hydroxyamino)methyl]phenoxy]ethyl]-6-

methyl- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C16 H21 N3 O3  
 SR CA  
 LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPAT2, USPATFULL  
 DT.CA CAplus document type: Journal; Patent  
 RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)  
 RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

5 REFERENCES IN FILE CA (1907 TO DATE)  
 5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 138:82897  
 REFERENCE 2: 135:331438  
 REFERENCE 3: 131:351343  
 REFERENCE 4: 130:223293  
 REFERENCE 5: 128:13282


L53 ANSWER 12 OF 20 REGISTRY COPYRIGHT 2004 ACS on STN  
 RN 199114-40-4 REGISTRY  
 CN Benzaldehyde, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy] -,  
 1-oxime (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C16 H19 N3 O3  
 SR CA  
 LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPAT2, USPATFULL  
 DT.CA CAplus document type: Journal; Patent  
 RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)  
 RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

5 REFERENCES IN FILE CA (1907 TO DATE)  
 5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 138:82897



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1907 TO DATE)  
 4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:331438

REFERENCE 2: 131:351343

REFERENCE 3: 130:223293

REFERENCE 4: 128:13282

L53 ANSWER 15 OF 20 REGISTRY COPYRIGHT 2004 ACS on STN  
 RN 199114-37-9 REGISTRY

CN Benzaldehyde, 4-[(3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy] - (9CI)  
 (CA INDEX NAME)

FS 3D CONCORD


MF C18 H16 N2 O3

SR CA

LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

DT.CA CAplus document type: Patent

RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1907 TO DATE)  
 4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:331438

REFERENCE 2: 131:351343

REFERENCE 3: 130:223293

REFERENCE 4: 128:13282

L53 ANSWER 16 OF 20 REGISTRY COPYRIGHT 2004 ACS on STN  
 RN 199114-36-8 REGISTRY

REFERENCE 2: 135:331438

REFERENCE 3: 131:351343

REFERENCE 4: 130:223293

REFERENCE 5: 128:13282

L53 ANSWER 13 OF 20 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 199114-39-1 REGISTRY

CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-3-methoxy- (9CI) (CA INDEX NAME)

FS 3D CONCORD


MF C18 H16 N2 O4

SR CA

LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

DT.CA CAplus document type: Patent

RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1907 TO DATE)  
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:331438

REFERENCE 2: 131:351343

REFERENCE 3: 130:223293

REFERENCE 4: 128:13282

L53 ANSWER 14 OF 20 REGISTRY COPYRIGHT 2004 ACS on STN

RN 199114-38-0 REGISTRY

CN Benzaldehyde, 4-[(1,4-dihydro-1-methyl-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C17 H14 N2 O3


SR CA

LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

DT.CA CAplus document type: Patent

RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)

CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy] -  
 (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C17 H14 N2 O3  
 SR CA  
 LC STN Files: CA, CAPLUS, USPAT2, USPATFULL  
 DT.CA CAplus document type: Patent  
 RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1907 TO DATE)  
 4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:331438

REFERENCE 2: 131:351343

REFERENCE 3: 130:223293

REFERENCE 4: 128:13282

L53 ANSWER 17 OF 20 REGISTRY COPYRIGHT 2004 ACS on STN  
 RN 199114-35-7 REGISTRY

CN Benzaldehyde, 4-[(2-methyl-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl)ethoxy] - (9CI) (CA INDEX NAME)

FS 3D CONCORD


MF C17 H15 N3 O3

SR CA

LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

DT.CA CAplus document type: Patent

RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1907 TO DATE)  
 4 REFERENCES IN FILE CAPLUS (1907 TO DATE)


REFERENCE 1: 135:331438

REFERENCE 2: 131:351343

REFERENCE 3: 130:223293

REFERENCE 4: 128:13282

L53 ANSWER 18 OF 20 REGISTRY COPYRIGHT 2004 ACS on STN  
 RN 199114-34-6 REGISTRY  
 CN Benzaldehyde, 4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA  
 INDEX NAME)  
 FS 3D CONCORD  
 MF C19 H18 N2 O3  
 SR CA  
 LC STN Files: CA, CAPLUS, USPAT2, USPATFULL  
 DT.CA CAplus document type: Patent  
 RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1907 TO DATE)  
 4 REFERENCES IN FILE CAPLUS (1907 TO DATE)


REFERENCE 1: 135:331438

REFERENCE 2: 131:351343

REFERENCE 3: 130:223293

REFERENCE 4: 128:13282

L53 ANSWER 19 OF 20 REGISTRY COPYRIGHT 2004 ACS on STN  
 RN 199114-33-5 REGISTRY  
 CN Benzaldehyde, 4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA  
 INDEX NAME)  
 FS 3D CONCORD  
 MF C18 H16 N2 O3  
 SR CA  
 LC STN Files: CA, CAPLUS, USPAT2, USPATFULL  
 DT.CA CAplus document type: Patent  
 RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1907 TO DATE)

## 4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:331438

REFERENCE 2: 131:351343

REFERENCE 3: 130:223293

REFERENCE 4: 128:13282

L53 ANSWER 20 OF 20 REGISTRY COPYRIGHT 2004 ACS on STN

RN 199114-32-4 REGISTRY

CN Benzaldehyde, 4-[2-(4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)

FS 3D CONCORD


MF C17 H14 N2 O3

SR CA

LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

DT.CA CAplus document type: Patent

RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1907 TO DATE)

4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:331438

REFERENCE 2: 131:351343

REFERENCE 3: 130:223293

REFERENCE 4: 128:13282

=&gt; d his

(FILE 'HOME' ENTERED AT 14:07:04 ON 24 AUG 2004)  
SET COST OFF

FILE 'REGISTRY' ENTERED AT 14:07:14 ON 24 AUG 2004

L1 STR  
 L2 0 S L1 CSS SAM  
 L3 STR L1  
 L4 SCR 2039 OR 2127 OR 0250 OR 2049 OR 2048 OR 2053 OR 2052 OR 205  
 L5 SCR 1993 AND 1839  
 L6 SCR 1406 OR 382 OR 356  
 L7 0 S L3 AND L5 AND L6 NOT L4 CSS SAM

FILE 'HCAPLUS' ENTERED AT 14:21:58 ON 24 AUG 2004

L8 4 S (US6310069 OR US6114526 OR US5985884 OR US5885997) /PN OR IN96  
 E LOHRAY V/AU  
 L9 47 S E4-E10

L10 E LOHRAY B/AU  
 121 S E4-E10  
 E PARASELLI R/AU  
 L11 12 S E4  
 E GURRAM R/AU  
 L12 11 S E4  
 E RAMANUJAM R/AU  
 L13 48 S E3,E4  
 E CHAKRABARTI R/AU  
 L14 154 S E3-E7,E15-E16  
 E PAKALA S/AU  
 L15 3 S E5  
 E REDDY/AP,CS  
 E REDDY/PA,CS  
 L16 385 S E3-E61  
 E DR REDDY/PA,CS  
 L17 55 S E5-E37  
 L18 4 S L8 AND L9-L17  
 SEL RN

FILE 'REGISTRY' ENTERED AT 14:27:49 ON 24 AUG 2004

L19 123 S E1-E123  
 L20 47 S L19 AND NCNC3-C6/ES  
 L21 41 S L20 AND 46.150.18/RID  
 L22 13 S L21 AND 3/NR  
 L23 11 S L22 NOT NITRO  
 L24 76 S L19 NOT L20  
 L25 51 S L24 AND NCNC3/ES  
 L26 44 S L25 AND 46.150.18/RID  
 L27 17 S L26 AND 2/NR  
 L28 16 S L27 NOT NITRO  
 L29 9 S L28 NOT ALDEHYDE  
 L30 3 S L29 AND (C12H12N2O OR C15H15N3O4)  
 L31 1 S L29 AND C16H21N3O3  
 L32 5 S L29 NOT L30,L31  
 L33 56 S L19 AND S/ELS  
 L34 53 S L33 AND 46.150.18/RID  
 L35 2 S L34 AND SC4-NCNC3/ES  
 L36 1 S L35 AND 3/NR  
 L37 12 S L19 AND NCNC3/ES AND 46.150.18/RID AND 2/NR NOT L32  
 L38 2 S L37 AND (C16H21N3O3 OR C16H19N3O3)  
 L39 100 S L19 AND 46.150.18/RID  
 L40 57 S L39 AND ETHOXY  
 L41 15 S L40 AND ALDEHYDE  
 L42 1 S C17H15N3O3 AND L41  
 L43 42 S L40 NOT L41  
 L44 14 S L43 NOT NCSC2/ES  
 L45 19 S L23,L32,L36,L38  
 L46 81 S L39 NOT L45  
 L47 29 S L46 NOT S/ELS  
 L48 24 S L47 NOT NITRO  
 L49 23 S L48 NOT ACETAMIDE  
 L50 19 S L49 NOT NCOC2/ES  
 L51 15 S L50 AND NR>=2  
 L52 11 S L51 NOT NOCNC/ES  
 L53 20 S L45,L42

FILE 'HCAOLD' ENTERED AT 15:01:23 ON 24 AUG 2004

L54 0 S L53

FILE 'HCAPLUS' ENTERED AT 15:01:26 ON 24 AUG 2004

L55 5 S L53

L56 5 S L55 AND L8-L18

FILE 'USPATFULL, USPAT2' ENTERED AT 15:02:09 ON 24 AUG 2004  
L57 9 S L53

FILE 'REGISTRY' ENTERED AT 15:05:28 ON 24 AUG 2004

=> fil hcplus  
FILE 'HCPLUS' ENTERED AT 15:06:55 ON 24 AUG 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Aug 2004 VOL 141 ISS 9  
FILE LAST UPDATED: 23 Aug 2004 (20040823/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d 156 all hitstr tot

L56 ANSWER 1 OF 5 HCPLUS COPYRIGHT 2004 ACS on STN  
AN 2002:418362 HCPLUS  
DN 138:82897  
ED Entered STN: 04 Jun 2002  
TI Synthesis and biological activity of novel pyrimidinone containing thiazolidinedione derivatives  
AU Madhavan, Gurram R.; Chakrabarti, Ranjan; Vikramadithyan, Reeba K.; Mamidi, Rao N. V. S.; Balraju, V.; Rajesh, B. M.; Misra, Parimal; Kumar, Sunil K. B.; Lohray, Braj B.; Lohray, Vidya B.; Rajagopalan, Ramanujam  
CS Dr. Reddy's Research Foundation, Hyderabad, 500 050, India  
SO Bioorganic & Medicinal Chemistry (2002), 10(8), 2671-2680  
CODEN: BMECEP; ISSN: 0968-0896  
PB Elsevier Science Ltd.  
DT Journal  
LA English  
CC 1-3 (Pharmacology)  
OS CASREACT 138:82897  
AB A series of pyrimidinone derivs. of thiazolidinediones were synthesized. Their biol. activity were evaluated in insulin resistant, hyperglycemic and obese db/db mice. In vitro PPAR $\gamma$  transactivation assay was performed in HEK 293T cells. PMT13 showed the best biol. activity in this series. PMT13 (5-[4-[2-[2-ethyl-4-methyl-6-oxo-1,6-dihydro-1-pyrimidinyl]ethoxy]phenylmethyl]thiazolidine-2,4-dione) showed better plasma glucose, triglyceride and insulin-lowering activity in db/db mice than rosiglitazone and pioglitazone. PMT13 showed better PPAR $\gamma$  transactivation than the standard compds. Pharmacokinetic study in Wistar rats showed good systemic exposure of PMT13. Twenty-eight day oral toxicity study in Wistar rats did not show any treatment-related adverse effects.  
ST pyrimidinone thiazolidinedione deriv prepn structure activity antidiabetic

obesity  
 IT Antidiabetic agents  
 Hyperglycemia  
 Obesity  
 Structure-activity relationship  
 (synthesis and structure-activity of novel pyrimidinone containing thiazolidinedione derivs.)  
 IT Glycerides, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (synthesis and structure-activity of novel pyrimidinone containing thiazolidinedione derivs.)  
 IT Peroxisome proliferator-activated receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 ( $\gamma$ ; synthesis and structure-activity of novel pyrimidinone containing thiazolidinedione derivs.)  
 IT 50-99-7, D-Glucose, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (blood; synthesis and structure-activity of novel pyrimidinone containing thiazolidinedione derivs.)  
 IT 9004-10-8, Insulin, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (synthesis and structure-activity of novel pyrimidinone containing thiazolidinedione derivs.)  
 IT 199113-95-6P  
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (synthesis and structure-activity of novel pyrimidinone containing thiazolidinedione derivs.)  
 IT 199113-79-6P 199113-81-0P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (synthesis and structure-activity of novel pyrimidinone containing thiazolidinedione derivs.)  
 IT 199113-92-3P 199113-93-4P 199113-94-5P 199113-96-7P 199114-01-7P  
 199114-02-8P 199114-11-9P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (synthesis and structure-activity of novel pyrimidinone containing thiazolidinedione derivs.)  
 IT 71-30-7 141-84-4, 2-Thioxo-4-thiazolidinone 2295-31-0,  
 Thiazolidine-2,4-dione 6622-92-0 16673-85-1 16858-16-5 16858-50-7  
 52191-15-8, 4-(2-Bromoethoxy)benzaldehyde 90565-51-8 199114-65-3  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (synthesis and structure-activity of novel pyrimidinone containing thiazolidinedione derivs.)  
 IT 14631-20-0P 199113-77-4P 199113-78-5P 199113-80-9P 199114-10-8P  
 199114-24-4P 199114-25-5P 199114-26-6P 199114-27-7P 199114-28-8P  
 199114-31-3P 199114-40-4P 199114-41-5P  
 199114-42-6P 199114-53-9P 199114-59-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (synthesis and structure-activity of novel pyrimidinone containing thiazolidinedione derivs.)

RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Aldo, S; J Med Chem 1995, V38, P4806
- (2) Anon; Scrip 1997, V2282, P21
- (3) Anon; Scrip 2001, V2668, P23
- (4) Atwal, K; J Med Chem 1992, V35, P475
- (5) Braj, B; J Med Chem 1998, V41, P1619

(6) Brown, D; *The Pyrimidines* 1994, P188  
 (7) DeFronzo, R; *Diabetologia* 1992, V35, P389 HCAPLUS  
 (8) Kliewer, S; *Cell* 1995, V83, P813 HCAPLUS  
 (9) Lehman, J; *J Biol Chem* 1995, V270, P12953  
 (10) Malamas, M; *Eur J Med Chem* 2001, V36, P31 HCAPLUS  
 (11) Nate, H; *Chem Pharm Bull* 1987, V35, P2394 HCAPLUS  
 (12) Patel, J; *Diabetes* 1997, V46(Suppl 1)  
 (13) Patel, J; *Diabetes* 1997, V46(Abstr 0578)  
 (14) Saltiel, A; *Diabetes* 1996, V45, P1661 HCAPLUS  
 (15) Wilson, T; *J Med Chem* 1996, V39, P665


IT 199114-40-4P 199114-41-5P 199114-42-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis and structure-activity of novel pyrimidinone containing thiazolidinedione derivs.)


RN 199114-40-4 HCAPLUS

CN Benzaldehyde, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, 1-oxime (9CI) (CA INDEX NAME)




RN 199114-41-5 HCAPLUS

CN 4(3H)-Pyrimidinone, 2-ethyl-3-[2-[4-[(hydroxyamino)methyl]phenoxy]ethyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 199114-42-6 HCAPLUS

CN Urea, N-[[4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]phenyl]methyl]-N-hydroxy- (9CI) (CA INDEX NAME)



L56 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:792332 HCAPLUS

DN 135:331438

ED Entered STN: 31 Oct 2001

TI Preparation of heterocyclic compounds for the treatment of diabetes and related diseases

IN Lohray, Vidya Bhushan; Lohray, Braj Bhushan;  
Paraselli, Rao Bheema; Gurram, Ranga Madhavan;

Ramanujam, Rajagopalan; Chakrabarti, Ranjan;  
Pakala, Sarma K. S.

PA Reddy's Research Foundation, India; Reddy-Cheminor Inc.  
SO U.S., 35 pp., Cont.-in-part of U.S. 5,985,884.  
CODEN: USXXAM

DT Patent

LA English

IC ICM A01K031-505

ICS C07D239-02; C07D239-70

NCL 514256000


CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))  
Section cross-reference(s): 1, 63

FAN.CNT 4


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6310069	B1	20011030	US 2000-535387	20000324 <--
	US 5885997	A	19990323	US 1996-777627	19961231 <--
	US 5985884	A	19991116	US 1997-884816	19970630 <--
PRAI	US 1996-777627	A2	19961231		
	US 1997-884816	A2	19970630		
	IN 1996-MA1150	A	19960701 <--		

CLASS

	PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
	US 6310069	ICM	A01K031-505
		ICS	C07D239-02; C07D239-70
		NCL	514256000
	US 5885997	ECLA	C07D413/12; C07D413/12; C07D413/12; C07D417/12; C07D417/12; C07D471/04; C07D495/04 <--
	US 5985884	ECLA	C07D239/36B; C07D239/46C3; C07D239/88; C07D277/34; C07D413/12; C07D413/12; C07D413/12; C07D413/12; C07D417/12; C07D417/12; C07D471/04; C07D495/04 <--
OS	MARPAT 135:331438		
GI			



I



II

AB The title compds. [I; one of X, Y, Z = C(O), C(S) and one of the remaining of X, Y, Z = C or C:C; R1-R3 = H, halo, OH, etc.; n = 1-4; Ar = (un)substituted divalent aryl, heteroaryl; R4 = H, halo, alkyl or forms a

bond together with the adjacent group A; A = N, CR5 (wherein R5 = H, halo, alkyl or R5 forms a bond together with R4); B = O, S when A = CR5 and B = O when A = N], novel antidiabetic compds., were prepared and formulated. Thus, reacting 4-[2-(2-ethyl-4-methyl-6-oxo-1,6-dihydro-1-pyrimidinyl)ethoxy]benzaldehyde (preparation given) with thiazolidine-2,4-dione afforded II which showed 67% maximum reduction in blood glucose level at 100 mg/kg/day (6 days treatment) in mice.

ST heterocycle prepn antidiabetic

IT Antidiabetic agents

(preparation of heterocyclic compds. for the treatment of diabetes and related diseases)

IT 199113-77-4P 199113-78-5P 199113-79-6P 199113-80-9P 199113-83-2P  
 199113-85-4P 199113-86-5P 199113-88-7P 199113-89-8P 199113-93-4P  
 199113-95-6P 199113-98-9P 199114-00-6P 199114-02-8P 199114-10-8P  
 199114-12-0P 199114-15-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of heterocyclic compds. for the treatment of diabetes and related diseases)

IT 199113-81-0P 199113-82-1P 199113-84-3P 199113-87-6P 199113-90-1P  
 199113-91-2P 199113-92-3P 199113-94-5P 199113-96-7P 199113-97-8P  
 199113-99-0P 199114-01-7P 199114-03-9P 199114-04-0P 199114-05-1P  
 199114-06-2P 199114-07-3P 199114-08-4P 199114-09-5P 199114-11-9P  
 199114-13-1P 199114-14-2P 199114-16-4P 199114-17-5P 199114-18-6P  
 199114-19-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic compds. for the treatment of diabetes and related diseases)

IT 121-33-5, Vanillin 123-08-0, 4-Hydroxybenzaldehyde 140-88-5, Ethyl acrylate 491-36-1, 4-Oxo-3,4-dihydroquinazoline 1769-24-0 2295-31-0, Thiazolidine-2,4-dione 2346-24-9 3137-64-2 4141-08-6, 2-Amino-N-methylbenzamide 6622-92-0 13288-06-7 14631-20-0 16673-85-1 16858-16-5 16858-50-7 18593-45-8 27738-96-1, Carbonisocyanatidic chloride 28279-12-1 52191-15-8, 4-(2-Bromoethoxy)benzaldehyde 52421-76-8 90565-51-8 199114-61-9 199114-62-0 199114-63-1 199114-64-2 199114-65-3 199114-66-4

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of heterocyclic compds. for the treatment of diabetes and related diseases)

IT 172648-06-5P 179087-93-5P 199114-24-4P 199114-25-5P 199114-26-6P  
 199114-27-7P 199114-28-8P 199114-29-9P 199114-30-2P 199114-31-3P  
 199114-32-4P 199114-33-5P 199114-34-6P  
 199114-35-7P 199114-36-8P 199114-37-9P  
 199114-38-0P 199114-39-1P 199114-40-4P  
 199114-41-5P 199114-42-6P 199114-43-7P 199114-44-8P  
 199114-45-9P 199114-46-0P 199114-47-1P  
 199114-48-2P 199114-49-3P 199114-50-6P 199114-51-7P  
 199114-52-8P 199114-53-9P 199114-54-0P 199114-55-1P  
 199114-56-2P 199114-57-3P 199114-59-5P 199114-60-8P  
 250256-31-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of heterocyclic compds. for the treatment of diabetes and related diseases)

RE.CNT 95 THERE ARE 95 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 RE

- (1) Ainsworth; US 5153210 1992 HCPLUS
- (2) Anon; JP 912575
- (3) Anon; 1980 HCPLUS

- (4) Anon; EP 008203 A 1980 HCAPLUS
- (5) Anon; EP 5355524 1984
- (6) Anon; EP 0139421 1985 HCAPLUS
- (7) Anon; EP 155845 A 1985 HCAPLUS
- (8) Anon; AU 570067 1985 HCAPLUS
- (9) Anon; GB 8528633 1986
- (10) Anon; EP 0207581 1987 HCAPLUS
- (11) Anon; EP 236624 1987 HCAPLUS
- (12) Anon; JP 62175458 1987 HCAPLUS
- (13) Anon; EP 0306228 1989 HCAPLUS
- (14) Anon; EP 0332331 1989 HCAPLUS
- (15) Anon; EP 0332332 1989 HCAPLUS
- (16) Anon; EP 0337819 1989 HCAPLUS
- (17) Anon; JP 6452765 1989
- (18) Anon; EP 0356214 1990 HCAPLUS
- (19) Anon; EP 0381371 1990
- (20) Anon; EP 03974531 1990
- (21) Anon; EP 0415605 1991 HCAPLUS
- (22) Anon; EP 0419035 1991 HCAPLUS
- (23) Anon; EP 0428312 1991 HCAPLUS
- (24) Anon; EP 0439321 1991 HCAPLUS
- (25) Anon; EP 0441605 1991 HCAPLUS
- (26) Anon; EP 0454501 1991 HCAPLUS
- (27) Anon; WO 9112003 1991 HCAPLUS
- (28) Anon; WO 9207838 1992 HCAPLUS
- (29) Anon; WO 9207850 1992 HCAPLUS
- (30) Anon; EP 0236624 1993 HCAPLUS
- (31) Anon; EP 0528734 1993 HCAPLUS
- (32) Anon; EP 0543662 1993 HCAPLUS
- (33) Anon; EP 0604983 1994 HCAPLUS
- (34) Anon; EP 0612743 1994 HCAPLUS
- (35) Anon; EP 590793 A 1994 HCAPLUS
- (36) Anon; EP 605228 A 1994 HCAPLUS
- (37) Anon; WO 9405659 1994 HCAPLUS
- (38) Anon; WO 9425026 1994 HCAPLUS
- (39) Anon; WO 9426720 1994 HCAPLUS
- (40) Anon; EP 0643050 1995 HCAPLUS
- (41) Anon; EP 0676398 1995 HCAPLUS
- (42) Anon; EP 0678511 1995 HCAPLUS
- (43) Anon; EP 645387 A 1995 HCAPLUS
- (44) Anon; JP 7138258 1995
- (45) Anon; WO 9507697 1995 HCAPLUS
- (46) Anon; WO 9521608 1995 HCAPLUS
- (47) Anon; WO 9526347 1995 HCAPLUS
- (48) Anon; WO 9535108 1995 HCAPLUS
- (49) Anon; EP 0708098 1996 HCAPLUS
- (50) Anon; EP 0733631 1996 HCAPLUS
- (51) Anon; JP 2558473 1996 HCAPLUS
- (52) Anon; EP 745600 A 1996 HCAPLUS
- (53) Anon; WO 9605186 1996 HCAPLUS
- (54) Anon; WO 9611196 1996 HCAPLUS
- (55) Anon; WO 9626207 1996 HCAPLUS
- (56) Anon; WO 9741097 1996 HCAPLUS
- (57) Anon; EP 0783888 1997 HCAPLUS
- (58) Anon; EP 0787727 1997 HCAPLUS
- (59) Anon; JP A0912575 1997
- (60) Barrie, C; Journal of Medicinal Chemistry 1994, V37(23), P3977
- (61) Cantello; US 5478851 1995 HCAPLUS
- (62) Clark; US 5036079 1991 HCAPLUS
- (63) Clark; US 5130379 1992 HCAPLUS
- (64) Clark, D; J Med Chem 1991, V34, P319 HCAPLUS
- (65) de Nanteuil; US 5296605 1994 HCAPLUS
- (66) de Nanteuil; US 5330999 1994 HCAPLUS


(67) de Nanteuil, G; Arzneittel Forschung/Drug Design 1995, V45(II), P1176  
 (68) Dow; US 5498621 1996 HCAPLUS  
 (69) Dow, R; J Med Chem 1991, V34, P1538 HCAPLUS  
 (70) Goldstein; US 5037842 1991 HCAPLUS  
 (71) Goldstein, S; J Med Chem 1993, V36, P2238 HCAPLUS  
 (72) Hindley; US 5002953 1991 HCAPLUS  
 (73) Hindley; US 5521201 1996 HCAPLUS  
 (74) Hisatome; abstract of Chem Lett 1993, 8, P1357 HCAPLUS  
 (75) Hulin, B; J Med Chem 1992, V35(10), P1853 HCAPLUS  
 (76) Husain; Pharmazie 1982, V37(H6), P408  
 (77) Khan; Pharmazie 1988, V43(12), P864 HCAPLUS  
 (78) Khan, A; abstract of Pharmazie 1993, V43(12), P864 HCAPLUS  
 (79) Malamas; US 5420146 1995 HCAPLUS  
 (80) Malamas; US 5468762 1995 HCAPLUS  
 (81) Malamas; US 5480896 1996 HCAPLUS  
 (82) Meguro; US 4725610 1988 HCAPLUS  
 (83) Messier; Behavioral Brain Research 1996, V75, P1 HCAPLUS  
 (84) Nagao; US 5710152 1998 HCAPLUS  
 (85) Olefsky; US 5478852 1995 HCAPLUS  
 (86) Regnier; US 5478853 1995 HCAPLUS  
 (87) Rise; abstract of Acta Chem Scand 1989, V43(5), P489 HCAPLUS  
 (88) Schnur; US 4342771 1982 HCAPLUS  
 (89) Schnur; US 4367234 1983 HCAPLUS  
 (90) Shukla; Indian J Chem 1979, V17B, P651 HCAPLUS  
 (91) Sohda, T; J Med Chem 1992, V35(14), P2617 HCAPLUS  
 (92) Taskasi, S; Chemical Pharmaceutical Bulletin 1982, V30(10), P3580  
 (93) Whitcomb, R; Expert Opinion on Investigational Drugs 1995, V4(12), P1299  
 HCAPLUS  
 (94) Yano; US 5521202 1996 HCAPLUS  
 (95) Yoshioka; US 4873255 1989 HCAPLUS

IT 199114-32-4P 199114-33-5P 199114-34-6P  
 199114-35-7P 199114-36-8P 199114-37-9P  
 199114-38-0P 199114-39-1P 199114-40-4P  
 199114-41-5P 199114-42-6P 199114-45-9P  
 199114-46-0P 199114-47-1P 199114-48-2P  
 199114-51-7P 199114-52-8P 199114-54-0P  
 199114-56-2P 199114-57-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of heterocyclic compds. for the treatment of diabetes and  
 related diseases)


RN 199114-32-4 HCAPLUS

CN Benzaldehyde, 4- [2- (4-oxo-3 (4H) -quinazolinyl)ethoxy] - (9CI) (CA INDEX  
 NAME)




RN 199114-33-5 HCAPLUS

CN Benzaldehyde, 4- [2- (2-methyl-4-oxo-3 (4H) -quinazolinyl)ethoxy] - (9CI) (CA  
 INDEX NAME)




RN 199114-34-6 HCAPLUS

CN Benzaldehyde, 4-[(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 199114-35-7 HCAPLUS

CN Benzaldehyde, 4-[(2-methyl-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 199114-36-8 HCAPLUS

CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)




RN 199114-37-9 HCAPLUS


CN Benzaldehyde, 4-[(3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)




RN 199114-38-0 HCAPLUS  
 CN Benzaldehyde, 4-[(1,4-dihydro-1-methyl-4-oxo-2-quinazolinyl)methoxy] -  
 (9CI) (CA INDEX NAME)




RN 199114-39-1 HCAPLUS  
 CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-3-  
 methoxy- (9CI) (CA INDEX NAME)




RN 199114-40-4 HCAPLUS  
 CN Benzaldehyde, 4-[(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-  
 1-oxime (9CI) (CA INDEX NAME)




RN 199114-41-5 HCAPLUS  
 CN 4(3H)-Pyrimidinone, 2-ethyl-3-[(2-[(4-hydroxyamino)methyl]phenoxy)ethyl]-6-  
 methyl- (9CI) (CA INDEX NAME)




RN 199114-42-6 HCAPLUS  
 CN Urea, N-[4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]phenyl]methyl-N-hydroxy- (9CI) (CA INDEX NAME)




RN 199114-45-9 HCAPLUS  
 CN 4 (3H)-Pyrimidinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl-6-methyl- (9CI) (CA INDEX NAME)



RN 199114-46-0 HCAPLUS  
 CN 4 (3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl- (9CI) (CA INDEX NAME)




RN 199114-47-1 HCAPLUS  
 CN Benzenepropanoic acid,  $\alpha$ -bromo-4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 199114-48-2 HCAPLUS  
 CN Benzenepropanoic acid,  $\alpha$ -bromo-4-[2-(2-ethyl-4-oxo-3(4H)-

quinazolinyl)ethoxy] - , ethyl ester (9CI) (CA INDEX NAME)




RN 199114-51-7 HCAPLUS

CN Benzene propanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-alpha-hydroxy- (9CI) (CA INDEX NAME)




RN 199114-52-8 HCAPLUS

CN Benzene propanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-alpha-hydroxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 199114-54-0 HCAPLUS

CN Benzaldehyde, 4-[2-(2,5,6-trimethyl-4-oxothieno[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 199114-56-2 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 199114-57-3 HCAPLUS

CN Benzenepropanoic acid,  $\alpha$ -bromo-4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)

L56 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 1999:733038 HCAPLUS

DN 131:351343

ED Entered STN: 18 Nov 1999

TI Preparation of heterocyclic compounds for the treatment of diabetes and related diseases

IN Lohray, Vidya Bhushan; Lohray, Braj Bhushan;  
Paraselli, Rao Bheema; Gurram, Ranga Madhavan;  
Ramanujam, Rajagopalan; Chakrabarti, Ranjan;  
Pakala, Sarma K. S.

PA Reddy's Research Foundation, India; Reddy-Cheminor Inc.

SO U.S., 35 pp., Cont.-in-part of U.S. 5,885,997.

CODEN: USXXAM

DT Patent

LA English

IC ICM C07D417-12

ICS C07D239-02; C07D241-00; A61K031-505

NCL 514259000

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))


Section cross-reference(s): 1, 63

FAN.CNT 4


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5985884	A	19991116	US 1997-884816	19970630 <--
	US 5885997	A	19990323	US 1996-777627	19961231 <--
	US 6114526	A	20000905	US 1999-353286	19990714 <--
	US 6310069	B1	20011030	US 2000-535387	20000324 <--
	US 6573268	B1	20030603	US 2000-535388	20000324 <--
	US 2001031759	A1	20011018	US 2001-827009	20010405 <--
	US 6372750	B2	20020416		
	US 2002123502	A1	20020905	US 2001-32846	20011226 <--
PRAI	IN 1996-MA1150	A	19960701	<--	
	US 1996-777627	A2	19961231		
	US 1997-884816	A	19970630		
	US 1999-353286	A3	19990714		
	US 2000-535388	A3	20000324		
	US 2001-827009	A3	20010405		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
US 5985884	ICM	C07D417-12	
	ICS	C07D239-02; C07D241-00; A61K031-505	
	NCL	514259000	
US 5985884	ECLA	C07D239/36B; C07D239/46C3; C07D239/88; C07D277/34; C07D413/12; C07D413/12; C07D413/12; C07D413/12; C07D417/12; C07D417/12; C07D471/04; C07D495/04	<--
US 5885997	ECLA	C07D413/12; C07D413/12; C07D413/12; C07D417/12; C07D417/12; C07D471/04; C07D495/04	<--
US 6114526	ECLA	C07D239/36B; C07D239/46C3; C07D239/88; C07D277/34; C07D413/12; C07D413/12; C07D413/12; C07D413/12; C07D417/12; C07D417/12; C07D471/04; C07D495/04	<--
US 6573268	ECLA	C07D239/36B; C07D495/04; C07D239/46C3; C07D239/88; C07D277/34; C07D413/12; C07D413/12; C07D413/12; C07D413/12; C07D417/12; C07D417/12; C07D471/04; C07D495/04	<--
US 2002123502	ECLA	C07D239/36B; C07D413/12; C07D417/12; C07D417/12; C07D471/04; C07D495/04; C07D239/46C3; C07D239/88; C07D277/34; C07D413/12; C07D413/12	<--
OS MARPAT 131:351343 GI			



I



II

AB The title compds. [I; one of X, Y, Z = C(O), C(S) and one of the remaining of X, Y, Z = C and the other C:C; R1-R3 = H, halo, OH, etc.; n = 1-4; Ar = (un)substituted divalent aryl, heteroaryl; R4 = H, halo, alkyl or forms a bond together with the adjacent group A; A = N, CR5 (wherein R5 = H, halo, alkyl or R5 forms a bond together with R4); B = O, S when A = CR5 and B = O when A = N], novel antidiabetic compds., were prepared and formulated. Thus, reacting 4-[2-(2-ethyl-4-methyl-6-oxo-1,6-dihydro-1-pyrimidinyl)ethoxy]benzaldehyde (preparation given) with thiazolidine-2,4-dione afforded II which showed 67% maximum reduction in blood glucose level at 100 mg/kg/day (6 days treatment) in mice.

ST heterocycle prepn antidiabetic

IT Antidiabetic agents

(preparation of heterocyclic compds. for the treatment of diabetes and related diseases)

IT 199113-77-4P 199113-78-5P 199113-79-6P 199113-80-9P 199113-83-2P  
 199113-85-4P 199113-86-5P 199113-88-7P 199113-89-8P 199113-93-4P  
 199113-95-6P 199113-98-9P 199114-00-6P 199114-02-8P 199114-10-8P  
 199114-12-0P 199114-15-3P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of heterocyclic compds. for the treatment of diabetes and related diseases)

IT 199113-81-0P 199113-82-1P 199113-84-3P 199113-87-6P 199113-90-1P  
 199113-91-2P 199113-92-3P 199113-94-5P 199113-96-7P 199113-97-8P  
 199113-99-0P 199114-01-7P 199114-03-9P 199114-04-0P 199114-05-1P  
 199114-06-2P 199114-07-3P 199114-08-4P 199114-09-5P 199114-11-9P  
 199114-13-1P 199114-14-2P 199114-16-4P 199114-17-5P 199114-18-6P  
 199114-19-7P 199114-21-1P 199114-22-2P 199114-23-3P 250256-30-5P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of heterocyclic compds. for the treatment of diabetes and related diseases)

IT 121-33-5, Vanillin 123-08-0, 4-Hydroxybenzaldehyde 140-88-5, Ethyl acrylate 491-36-1, 4-Oxo-3,4-dihydroquinazoline 1769-24-0 2295-31-0, Thiazolidine-2,4-dione 2346-24-9 3137-64-2 4141-08-6, 2-Amino-N-methylbenzamide 6622-92-0 13288-06-7 14631-20-0 16673-85-1 16858-16-5 16858-50-7 18593-45-8 27738-96-1, Carbonisocyanatidic chloride 28279-12-1 52191-15-8, 4-(2-Bromoethoxy)benzaldehyde 52421-76-8 90565-51-8 199114-61-9 199114-62-0 199114-63-1 199114-64-2 199114-65-3 199114-66-4  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of heterocyclic compds. for the treatment of diabetes and related diseases)

IT 172648-06-5P 179087-93-5P 199114-24-4P 199114-25-5P 199114-26-6P  
 199114-27-7P 199114-28-8P 199114-29-9P 199114-30-2P 199114-31-3P  
**199114-32-4P 199114-33-5P 199114-34-6P**  
**199114-35-7P 199114-36-8P 199114-37-9P**  
**199114-38-0P 199114-39-1P 199114-40-4P**  
**199114-41-5P 199114-42-6P 199114-43-7P 199114-44-8P**  
**199114-45-9P 199114-46-0P 199114-47-1P**  
**199114-48-2P 199114-49-3P 199114-50-6P 199114-51-7P**  
**199114-52-8P 199114-53-9P 199114-54-0P 199114-55-1P**  
**199114-56-2P 199114-57-3P 199114-59-5P 199114-60-8P**  
 250256-31-6P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of heterocyclic compds. for the treatment of diabetes and related diseases)


RE.CNT 84 THERE ARE 84 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE


- (1) Ainsworth; US 5153210 1992 HCPLUS
- (2) Anon; JP 09-12575 A HCPLUS
- (3) Anon; AU 570067 HCPLUS
- (4) Anon; GB 8528633
- (5) Anon; 1980 HCPLUS
- (6) Anon; EP 008203A 1980
- (7) Anon; EP 0139421 1985 HCPLUS
- (8) Anon; EP 155845 A 1985 HCPLUS
- (9) Anon; WO 9605186 1986 HCPLUS
- (10) Anon; EP 0207581 1987 HCPLUS
- (11) Anon; EP 0306228 1989 HCPLUS
- (12) Anon; EP 0332332 1989 HCPLUS
- (13) Anon; EP 0337819 1989 HCPLUS
- (14) Anon; JP 06-452765 1989

- (15) Anon; EP 0356214 1990 HCAPLUS
- (16) Anon; EP 0381371 1990 HCAPLUS
- (17) Anon; EP 0397453 1990 HCAPLUS
- (18) Anon; EP 0415605 1991 HCAPLUS
- (19) Anon; EP 0419035 1991 HCAPLUS
- (20) Anon; EP 0428312 1991 HCAPLUS
- (21) Anon; EP 0439321 1991 HCAPLUS
- (22) Anon; EP 0441605 1991 HCAPLUS
- (23) Anon; EP 0454501 1991 HCAPLUS
- (24) Anon; WO 9207838 1992 HCAPLUS
- (25) Anon; WO 9207850 1992 HCAPLUS
- (26) Anon; EP 0236624 1993 HCAPLUS
- (27) Anon; EP 0528734 1993 HCAPLUS
- (28) Anon; EP 0543662 1993 HCAPLUS
- (29) Anon; EP 0604983 1994 HCAPLUS
- (30) Anon; EP 0612743 1994 HCAPLUS
- (31) Anon; EP 590793 A 1994 HCAPLUS
- (32) Anon; EP 605227 A 1994 HCAPLUS
- (33) Anon; WO 9405659 1994 HCAPLUS
- (34) Anon; WO 9426720 1994 HCAPLUS
- (35) Anon; EP 0643050 1995 HCAPLUS
- (36) Anon; EP 0676398 1995 HCAPLUS
- (37) Anon; EP 0678511 1995 HCAPLUS
- (38) Anon; JP 07-138258 1995 HCAPLUS
- (39) Anon; EP 645387 A 1995 HCAPLUS
- (40) Anon; WO 9507697 1995 HCAPLUS
- (41) Anon; WO 9521608 1995 HCAPLUS
- (42) Anon; WO 9526347 1995 HCAPLUS
- (43) Anon; WO 9535108 1995 HCAPLUS
- (44) Anon; EP 0708098 1996 HCAPLUS
- (45) Anon; EP 0733631 1996 HCAPLUS
- (46) Anon; EP 745600 A 1996 HCAPLUS
- (47) Anon; WO 9611196 1996 HCAPLUS
- (48) Anon; WO 9626207 1996 HCAPLUS
- (49) Anon; EP 0783888 1997 HCAPLUS
- (50) Anon; EP 0787727 1997 HCAPLUS
- (51) Anon; JP 09-12575 1997 HCAPLUS
- (52) Anon; Behavioral Brain Research 1996, V75, P1
- (53) Anon; Chemical Pharmaceutical Bulletin 1982, V30(10), P3580
- (54) Cantello; US 5478851 1995 HCAPLUS
- (55) Cantello; Journal of Medicinal Chemistry 1994, V37(23), P3977 HCAPLUS
- (56) Clark; US 5036079 1991 HCAPLUS
- (57) Clark; US 5130379 1992 HCAPLUS
- (58) Clark, D; J Med Chem 1991, V34, P319 HCAPLUS
- (59) De Nanteuil; US 5296605 1994 HCAPLUS
- (60) De Nanteuil; US 5330999 1994 HCAPLUS
- (61) De Nanteuil, G; Arzneittel Forschung/Drug Design 1995, V45(II), P1176
- (62) Dow; US 5498621 1996 HCAPLUS
- (63) Dow, R; J Med Chem 1991, V34, P1538 HCAPLUS
- (64) Goldstein; US 5037842 1991 HCAPLUS
- (65) Goldstein, S; J Med Chem 1993, V36, P2238 HCAPLUS
- (66) Hindley; US 5002953 1991 HCAPLUS
- (67) Hindley; US 5521201 1996 HCAPLUS
- (68) Hulin, B; J Med Chem 1992, V35(10), P1853 HCAPLUS
- (69) Husain; Pharmazie 1982, V37(6), P408 HCAPLUS
- (70) Khan, A; Pharmazie 1988, V43(12), P864 HCAPLUS
- (71) Malamas; US 5420146 1995 HCAPLUS
- (72) Malamas; US 5468762 1995 HCAPLUS
- (73) Malamas; US 5480896 1996 HCAPLUS
- (74) Meguro; US 4725610 1988 HCAPLUS
- (75) Nagao; US 5710152 1998 HCAPLUS
- (76) Olefsky; US 5478852 1995 HCAPLUS
- (77) Regnier; US 5478853 1995 HCAPLUS


(78) Schnur; US 4342771 1982 HCPLUS  
 (79) Schnur; US 4367234 1983 HCPLUS  
 (80) Shukla, J; Indian Journal Chemical 1979, V17B(6), P651 HCPLUS  
 (81) Sohda, T; J Med Chem 1992, V35(14), P2617 HCPLUS  
 (82) Whitcomb, R; Expert Opinion on Investigational Drugs 1995, V4(12), P1299  
 HCPLUS  
 (83) Yano; US 5521202 1996 HCPLUS  
 (84) Yushioka; US 4873255 1989 HCPLUS  
 IT 199114-32-4P 199114-33-5P 199114-34-6P  
 199114-35-7P 199114-36-8P 199114-37-9P  
 199114-38-0P 199114-39-1P 199114-40-4P  
 199114-41-5P 199114-42-6P 199114-45-9P  
 199114-46-0P 199114-47-1P 199114-48-2P  
 199114-51-7P 199114-52-8P 199114-54-0P  
 199114-56-2P 199114-57-3P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of heterocyclic compds. for the treatment of diabetes and  
 related diseases)  
 RN 199114-32-4 HCPLUS  
 CN Benzaldehyde, 4-[2-(4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX  
 NAME)




RN 199114-33-5 HCPLUS  
 CN Benzaldehyde, 4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA  
 INDEX NAME)




RN 199114-34-6 HCPLUS  
 CN Benzaldehyde, 4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA  
 INDEX NAME)




RN 199114-35-7 HCPLUS  
 CN Benzaldehyde, 4-[2-(2-methyl-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl)ethoxy]-  
 (9CI) (CA INDEX NAME)




RN 199114-36-8 HCAPLUS  
 CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)




RN 199114-37-9 HCAPLUS  
 CN Benzaldehyde, 4-[(3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)




RN 199114-38-0 HCAPLUS  
 CN Benzaldehyde, 4-[(1,4-dihydro-1-methyl-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)




RN 199114-39-1 HCAPLUS  
 CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-3-methoxy- (9CI) (CA INDEX NAME)




RN 199114-40-4 HCAPLUS  
 CN Benzaldehyde, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, 1-oxime (9CI) (CA INDEX NAME)




RN 199114-41-5 HCAPLUS  
 CN 4 (3H)-Pyrimidinone, 2-ethyl-3-[2-[4-[(hydroxyamino)methyl]phenoxy]ethyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 199114-42-6 HCAPLUS  
 CN Urea, N-[(4-[(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]phenyl)methyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 199114-45-9 HCAPLUS  
 CN 4 (3H)-Pyrimidinone, 3-[(4-aminophenoxy)ethyl]-2-ethyl-6-methyl- (9CI) (CA INDEX NAME)




RN 199114-46-0 HCAPLUS  
 CN 4 (3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl- (9CI) (CA INDEX NAME)




RN 199114-47-1 HCAPLUS  
 CN Benzenepropanoic acid,  $\alpha$ -bromo-4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 199114-48-2 HCAPLUS  
 CN Benzenepropanoic acid,  $\alpha$ -bromo-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-51-7 HCAPLUS  
 CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)




RN 199114-52-8 HCAPLUS  
 CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]- $\alpha$ -hydroxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 199114-54-0 HCAPLUS

BN 159114-34-0 (CA INDEX NAME)  
CN Benzaldehyde, 4-[2-(2,5,6-trimethyl-4-oxothieno[2,3-d]pyrimidin-3(4H)-yl)ethoxy]-(9CI) (CA INDEX NAME)




RN 199114-56-2 HCAPLUS

CN 4 (3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 199114-57-3 HCAPLUS

CN Benzenepropanoic acid,  $\alpha$ -bromo-4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



L56 ANSWER 4 OF 5 HCPLUS COPYRIGHT 2004 ACS on STN

AN 1999:212642 HCAPLUS

DN 130:223293

ED      Entered STN: 05 Apr 1999

TI Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases

IN Lohray, Vidya Bhushan; Lohray, Braj Bhushan;  
Paraselli, Rao Bheema

PA Reddy's Research Foundation, India; Reddy-Cheminor, Inc.

SO U.S., 26 pp.

CODEN: USXXAM

DT Patent  
 LA English  
 IC ICM C07D417-12  
 ICS A61K031-425  
 NCL 514256000  
 CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference(s): 1  
 FAN.CNT 4



	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5885997	A	19990323	US 1996-777627	19961231 <--
	CA 2258949	AA	19971106	CA 1997-2258949	19970630 <--
WO 9741097	A2	19971106	WO 1997-US11522	19970630	
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9737198	A1	19971119	AU 1997-37198	19970630	
AU 744518	B2	20020228			
US 5985884	A	19991116	US 1997-884816	19970630 <--	
EP 958296	A1	19991124	EP 1997-934041	19970630 <--	
EP 958296	B1	20030730			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI					
BR 9711098	A	20000308	BR 1997-11098	19970630 <--	
CN 1275982	A	20001206	CN 1997-195778	19970630	
JP 2002515874	T2	20020528	JP 1997-539307	19970630	
IL 127296	A1	20030112	IL 1997-127296	19970630	
RU 2200161	C2	20030310	RU 1998-123195	19970630	
AT 246190	E	20030815	AT 1997-934041	19970630	
PT 958296	T	20031128	PT 1997-934041	19970630	
ES 2199366	T3	20040216	ES 1997-934041	19970630	
ZA 9705866	A	19980223	ZA 1997-5866	19970701 <--	
MX 9810782	A	20001130	MX 1998-10782	19981215	
NO 9806055	A	19981222	NO 1998-6055	19981222	
US 6114526	A	20000905	US 1999-353286	19990714 <--	
US 6310069	B1	20011030	US 2000-535387	20000324 <--	
US 6573268	B1	20030603	US 2000-535388	20000324 <--	
US 2001031759	A1	20011018	US 2001-827009	20010405 <--	
US 6372750	B2	20020416			
US 2002123502	A1	20020905	US 2001-32846	20011226 <--	
PRAI IN 1996-MA1150	A	19960701	<--		
US 1996-777627	A	19961231			
US 1997-884816	A	19970630			
WO 1997-US11522	W	19970630			
US 1999-353286	A3	19990714			
US 2000-535388	A3	20000324			
US 2001-827009	A3	20010405			

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 5885997	ICM	C07D417-12
	ICS	A61K031-425
	NCL	514256000
US 5885997	ECLA	C07D413/12; C07D413/12; C07D413/12; C07D417/12; C07D417/12; C07D471/04; C07D495/04
	WO 9741097	ECLA
US 5985884	ECLA	C07D239/36B; C07D239/46C3; C07D239/88; C07D277/34;

US 6114526 ECLA C07D413/12; C07D413/12; C07D413/12; C07D413/12; C07D417/12; C07D417/12; C07D471/04; C07D495/04 <--  
 C07D239/36B; C07D239/46C3; C07D239/88; C07D277/34;  
 C07D413/12; C07D413/12; C07D413/12; C07D413/12;  
 C07D417/12; C07D417/12; C07D471/04; C07D495/04 <--  
 C07D239/36B; C07D495/04; C07D239/46C3; C07D239/88;  
 C07D277/34; C07D413/12; C07D413/12; C07D413/12;  
 C07D413/12; C07D417/12; C07D417/12277B; C07D471/04 <--  
 US 2002123502 ECLA C07D239/36B; C07D413/12; C07D417/12; C07D417/12;  
 C07D471/04; C07D495/04; C07D239/46C3; C07D239/88;  
 C07D277/34; C07D413/12; C07D413/2; C07D413/12 <--

OS MARPAT 130:223293  
 GI



AB The present invention relates to novel antidiabetic compds., their tautomeric forms, their derivs., their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compns. containing them. This invention particularly relates to novel azolidinedione derivs., and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compns. containing them. Approx. 30 title compds. such as I (R = Pr, Me, Et, Bu, benzyl) and their quinazoline analogs were prepared in 66-99% yields, e.g., by condensation of aldehydes II with thiazolidine-2,4-dione. Antidiabetic data was given for several of the prepared compds. At 30 mg/kg/day, after 6 days, 5-[4-[2-[2-ethyl-4-methyl-6-oxo-1,5-dihydro-1-pyrimidinyl]ethoxyphenylmethyl] thiazolidine-2,4-dione reduced the blood glucose level 73%, lowered triglycerides 70% and also lowered cholesterol in the rat.

ST antidiabetic pyrimidinylethoxybenzylthiazolidinedione prepn;  
 thiazolidinedione pyrimidinylethoxybenzyl prepn

IT Antidiabetic agents  
 (preparation of pyrimidinylethoxybenzylthiazolidinediones)

IT 199113-79-6P 199113-83-2P 199113-88-7P 199113-89-8P 199113-98-9P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of pyrimidinylethoxybenzylthiazolidinediones)

IT 199113-82-1P 199113-85-4P 199113-93-4P 199113-95-6P 199113-97-8P  
 199114-00-6P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of pyrimidinylethoxybenzylthiazolidinediones)

IT 121-33-5, Vanillin 123-08-0, 4-Hydroxybenzaldehyde 140-88-5  
 491-36-1, 3,4-Dihydroquinazolin-4-one 1769-24-0 2295-31-0,  
 Thiazolidine-2,4-dione 2346-24-9 3137-64-2 3282-30-2, Pivaloyl  
 chloride 4141-08-6,  $\alpha$ -Amino-N-methylbenzamide 6622-92-0 13288-06-7  
 14631-20-0 16673-85-1 16858-16-5 16858-50-7 18593-45-8  
 28279-12-1 52191-15-8, 4-(2-Bromoethoxy)benzaldehyde 52421-76-8  
 90565-51-8 179087-93-5 199114-61-9 221208-19-1 221208-20-4  
 221208-21-5

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrimidinylethoxybenzylthiazolidinediones)

IT 199113-77-4P 199113-78-5P 199113-80-9P 199114-02-8P 199114-24-4P  
 199114-25-5P 199114-26-6P 199114-27-7P 199114-28-8P 199114-29-9P  
 199114-30-2P 199114-31-3P 199114-32-4P 199114-33-5P  
 199114-34-6P 199114-35-7P 199114-36-8P  
 199114-37-9P 199114-38-0P 199114-39-1P  
 199114-40-4P 199114-41-5P 199114-42-6P  
 199114-43-7P 199114-44-8P 199114-45-9P 199114-46-0P  
 199114-47-1P 199114-48-2P 199114-51-7P  
 199114-52-8P 199114-53-9P 199114-54-0P 221208-06-6P  
 221208-08-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrimidinylethoxybenzylthiazolidinediones)

IT 199113-81-0P 199113-84-3P 199113-86-5P 199113-87-6P 199113-90-1P  
 199113-91-2P 199113-92-3P 199113-94-5P 199113-96-7P 199113-99-0P  
 199114-03-9P 199114-04-0P 199114-05-1P 221207-99-4P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of pyrimidinylethoxybenzylthiazolidinediones)

RE.CNT 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Anon; EP 008203 A 1980 HCPLUS  
 (2) Anon; EP 155845 A 1985 HCPLUS  
 (3) Anon; EP 2139421 1985  
 (4) Anon; AU 570067 1985 HCPLUS  
 (5) Anon; GB 8528633 1986  
 (6) Anon; EP 0207581 1987 HCPLUS  
 (7) Anon; EP 0236624 1987 HCPLUS  
 (8) Anon; EP 0306228 1989 HCPLUS  
 (9) Anon; EP 0332331 1989 HCPLUS  
 (10) Anon; EP 0332332 1989 HCPLUS  
 (11) Anon; EP 0337819 1989 HCPLUS  
 (12) Anon; EP 0397453 1990 HCPLUS  
 (13) Anon; EP 0415605 1991 HCPLUS  
 (14) Anon; EP 0419035 1991 HCPLUS  
 (15) Anon; EP 0439321 1991 HCPLUS  
 (16) Anon; EP 0441605 1991 HCPLUS  
 (17) Anon; EP 0454501 1991 HCPLUS  
 (18) Anon; GB 9112003 1991  
 (19) Anon; GB 9207838 1992  
 (20) Anon; GB 9207850 1992  
 (21) Anon; EP 0528734 1993 HCPLUS  
 (22) Anon; EP 0543662 1993 HCPLUS  
 (23) Anon; EP 0604983 1994 HCPLUS  
 (24) Anon; EP 590793 A 1994 HCPLUS  
 (25) Anon; EP 605228 A 1994 HCPLUS  
 (26) Anon; GB 9405659 1994  
 (27) Anon; GB 9425026 1994  
 (28) Anon; EP 0676398 1995 HCPLUS  
 (29) Anon; EP 0678511 1995 HCPLUS  
 (30) Anon; EP 645387 A 1995 HCPLUS  
 (31) Anon; JP 7138258 1995  
 (32) Anon; GB 9507697 1995

(33) Anon; GB 9521608 1995  
 (34) Anon; GB 9535108 1995  
 (35) Anon; EP 745600 A 1996 HCPLUS  
 (36) Anon; EP 0783888 1997 HCPLUS  
 (37) Anon; EP 0787727 1997 HCPLUS  
 (38) Anon; Journal of Medicinal Chemistry 1994, V37(23)  
 (39) Answorth; US 5153210 1992 HCPLUS  
 (40) Cantello; US 5478851 1995 HCPLUS  
 (41) Clark; US 5036079 1991 HCPLUS  
 (42) Clark; US 5130797 1992  
 (43) de Nanteuil; US 5296605 1994 HCPLUS  
 (44) de Nanteuil; US 5330999 1994 HCPLUS  
 (45) de Nanteuil, G; Arzneittel Forschung/Drug Design 1995, V45(II), P1176  
 (46) Goldstein; US 5037842 1991 HCPLUS  
 (47) Goldstein; US 5334604 1994 HCPLUS  
 (48) Hindley; US 5002953 1991 HCPLUS  
 (49) Hindley; US 5521201 1996 HCPLUS  
 (50) Malamus; US 5420146 1995 HCPLUS  
 (51) Meguno; US 4725610 1988 HCPLUS  
 (52) Messler; Behavioural Brain Research 1996, V75, P1  
 (53) Olefsky; US 5478852 1995 HCPLUS  
 (54) Takashi; Chemical and Pharmaceutical Bulletin 1982, V30(10), P3580  
 (55) Whitcomb, R; "Thiazolidinediones", Expert Opinion on Investigational Drugs 1995, V4(12), P1299 HCPLUS  
 (56) Yano; US 5521202 1996 HCPLUS  
 (57) Yoshioka; US 4873255 1989 HCPLUS


IT 199114-32-4P 199114-33-5P 199114-34-6P  
 199114-35-7P 199114-36-8P 199114-37-9P  
 199114-38-0P 199114-39-1P 199114-40-4P  
 199114-41-5P 199114-42-6P 199114-45-9P  
 199114-46-0P 199114-47-1P 199114-48-2P  
 199114-51-7P 199114-52-8P 199114-54-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrimidinylethoxybenzylthiazolidinediones)


RN 199114-32-4 HCPLUS

CN Benzaldehyde, 4- [2- (4-oxo-3 (4H) -quinazolinyl)ethoxy] - (9CI) (CA INDEX NAME)



RN 199114-33-5 HCPLUS


CN Benzaldehyde, 4- [2- (2-methyl-4-oxo-3 (4H) -quinazolinyl)ethoxy] - (9CI) (CA INDEX NAME)



RN 199114-34-6 HCPLUS


CN Benzaldehyde, 4- [2- (2-ethyl-4-oxo-3 (4H) -quinazolinyl)ethoxy] - (9CI) (CA INDEX NAME)

INDEX NAME)




RN 199114-35-7 HCAPLUS

CN Benzaldehyde, 4-[(2-ethyl-4-oxo-2,3-dihydro-4H-pyrimidin-3-yl)ethoxy] - (9CI) (CA INDEX NAME)




RN 199114-36-8 HCAPLUS

CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy] - (9CI) (CA INDEX NAME)




RN 199114-37-9 HCAPLUS

CN Benzaldehyde, 4-[(3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy] - (9CI) (CA INDEX NAME)




RN 199114-38-0 HCAPLUS


CN Benzaldehyde, 4-[(1,4-dihydro-1-methyl-4-oxo-2-quinazolinyl)methoxy] - (9CI) (CA INDEX NAME)




RN 199114-39-1 HCAPLUS  
 CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-3-methoxy- (9CI) (CA INDEX NAME)




RN 199114-40-4 HCAPLUS  
 CN Benzaldehyde, 4-[(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-1-oxime (9CI) (CA INDEX NAME)




RN 199114-41-5 HCAPLUS  
 CN 4(3H)-Pyrimidinone, 2-ethyl-3-[(2-[(4-hydroxyamino)methyl]phenoxy]ethyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 199114-42-6 HCAPLUS  
 CN Urea, N-[(4-[(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]phenyl)methyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 199114-45-9 HCAPLUS  
 CN 4(3H)-Pyrimidinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl-6-methyl- (9CI)  
 (CA INDEX NAME)




RN 199114-46-0 HCAPLUS  
 CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl- (9CI) (CA INDEX NAME)




RN 199114-47-1 HCAPLUS  
 CN Benzene propanoic acid,  $\alpha$ -bromo-4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 199114-48-2 HCAPLUS  
 CN Benzene propanoic acid,  $\alpha$ -bromo-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 199114-51-7 HCAPLUS  
 CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)



RN 199114-52-8 HCAPLUS  
 CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]- $\alpha$ -hydroxy-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-54-0 HCAPLUS  
 CN Benzaldehyde, 4-[2-(2,5,6-trimethyl-4-oxothieno[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)




L56 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1997:740205 HCAPLUS  
 DN 128:13282  
 ED Entered STN: 24 Nov 1997  
 TI Preparation of thiazolidinediones and analogs as antidiabetics  
 IN Lohray, Vidya Bhushan; Lohray, Braj Bhushan;  
 Paraselli, Rao Bheema; Gurram, Ranga Madhavan;  
 Ramanujam, Rajagopalan; Chakrabarti, Ranjan;  
 Pakala, Sarma K. S.  
 PA Dr. Reddy's Research Foundation, India; Reddy-Cheminor,  
 Inc.  
 SO PCT Int. Appl., 112 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM C07D  
 CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference(s): 1  
 FAN.CNT 4  
 PATENT NO. KIND DATE APPLICATION NO. DATE  
 PI WO 9741097 A2 19971106 WO 1997-US11522 19970630  
 W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,

DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ,	LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,	PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ,	VN, YU, ZW
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,	GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,	GN, ML, MR, NE, SN, TD, TG	
US 5885997	A 19990323	US 1996-777627	19961231 <--
AU 9737198	A1 19971119	AU 1997-37198	19970630
AU 744518	B2 20020228		
EP 958296	A1 19991124	EP 1997-934041	19970630 <--
EP 958296	B1 20030730		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI			
BR 9711098	A 20000308	BR 1997-11098	19970630 <--
JP 2002515874	T2 20020528	JP 1997-539307	19970630
IL 127296	A1 20030112	IL 1997-127296	19970630
RU 2200161	C2 20030310	RU 1998-123195	19970630
AT 246190	E 20030815	AT 1997-934041	19970630
MX 9810782	A 20001130	MX 1998-10782	19981215
NO 9806055	A 19981222	NO 1998-6055	19981222
PRAI US 1996-777627	A 19961231		
IN 1996-MA1150	A 19960701	<--	
WO 1997-US11522	W 19970630		

**CLASS**

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9741097	ICM	C07D
WO 9741097	ECLA	C07D239/36B; C07D239/46C3; C07D239/88; C07D277/34; C07D413/12; C07D413/12; C07D413/12; C07D417/12; C07D417/12; C07D471/04; C07D495/04
US 5885997	ECLA	C07D413/12; C07D413/12; C07D413/12; C07D417/12; C07D417/12; C07D471/04; C07D495/04

OS MARPAT 128:13282  
GI



AB Title compds. [I; A = N, CR<sub>5</sub>; B = O or S; R = CHR<sub>4</sub>ZO(CH<sub>2</sub>)<sub>n</sub>R<sub>1</sub>; R<sub>1</sub> = (un)substituted pyrimidinyl, -quinazolinyl, etc.; R<sub>4</sub>,R<sub>5</sub> = H, halo, alkyl; R<sub>4</sub>R<sub>5</sub> = bond; Z = divalent aromatic or heterocyclic group; n = 1-4] were prepared. Thus, 4-methyl-2-propyl-1,6-dihydro-6-pyrimidinone was N-alkylated by 4-(BrCH<sub>2</sub>CH<sub>2</sub>HO)C<sub>6</sub>H<sub>4</sub>CHO and the product condensed with thiazolidine-2,4-dione to give, after hydrogenation, title compound II. Data for biol. activity of I were given.

ST thiazolidinedione prepn antidiabetic

## IT Antidiabetic agents

## Hypolipemic agents

(preparation of thiazolidinediones and analogs as antidiabetics)

IT	199113-77-4P	199113-78-5P	199113-79-6P	199113-80-9P	199113-81-0P
	199113-82-1P	199113-83-2P	199113-84-3P	199113-85-4P	199113-86-5P
	199113-87-6P	199113-88-7P	199113-89-8P	199113-90-1P	199113-91-2P
	199113-92-3P	199113-93-4P	199113-94-5P	199113-95-6P	199113-96-7P
	199113-97-8P	199113-98-9P	199113-99-0P	199114-00-6P	199114-01-7P

199114-02-8P 199114-03-9P 199114-04-0P 199114-05-1P 199114-06-2P  
 199114-07-3P 199114-08-4P 199114-09-5P 199114-10-8P 199114-11-9P  
 199114-12-0P 199114-13-1P 199114-14-2P 199114-15-3P 199114-16-4P  
 199114-17-5P 199114-18-6P 199114-19-7P 199114-20-0P 199114-21-1P  
 199114-22-2P 199114-23-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of thiazolidinediones and analogs as antidiabetics)

IT 121-33-5, Vanillin 123-08-0, 4-Hydroxybenzaldehyde 140-88-5  
 491-36-1, 4-Oxo-3,4-dihydroquinazoline 1769-24-0 2295-31-0,  
 Thiazolidine-2,4-dione 2346-24-9, 2-Thioxo-1,3-oxazolidin-4-one  
 3137-64-2 4141-08-6, 2-Amino-N-methylbenzamide 6622-92-0 14631-20-0  
 16673-85-1 16858-16-5 16858-50-7 18593-45-8 28279-12-1  
 52191-15-8, 4-(2-Bromoethoxy)benzaldehyde 52421-76-8 57279-70-6,  
 4-(2-Bromoethoxy)-1-nitrobenzene 90565-51-8 199114-61-9 199114-62-0  
 199114-63-1 199114-64-2 199114-65-3 199114-66-4

RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of thiazolidinediones and analogs as antidiabetics)


IT 172648-06-5P 179087-93-5P 199114-24-4P 199114-25-5P 199114-26-6P  
 199114-27-7P 199114-28-8P 199114-29-9P 199114-30-2P 199114-31-3P  
 199114-32-4P 199114-33-5P 199114-34-6P  
 199114-35-7P 199114-36-8P 199114-37-9P  
 199114-38-0P 199114-39-1P 199114-40-4P  
 199114-41-5P 199114-42-6P 199114-43-7P 199114-44-8P  
 199114-45-9P 199114-46-0P 199114-47-1P  
 199114-48-2P 199114-49-3P 199114-50-6P 199114-51-7P  
 199114-52-8P 199114-53-9P 199114-54-0P 199114-55-1P  
 199114-56-2P 199114-57-3P 199114-58-4P 199114-59-5P  
 199114-60-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of thiazolidinediones and analogs as antidiabetics)


IT 199114-32-4P 199114-33-5P 199114-34-6P  
 199114-35-7P 199114-36-8P 199114-37-9P  
 199114-38-0P 199114-39-1P 199114-40-4P  
 199114-41-5P 199114-42-6P 199114-45-9P  
 199114-46-0P 199114-47-1P 199114-48-2P  
 199114-51-7P 199114-52-8P 199114-54-0P  
 199114-56-2P 199114-57-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of thiazolidinediones and analogs as antidiabetics)

RN 199114-32-4 HCAPLUS  
 CN Benzaldehyde, 4-[2-(4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 199114-33-5 HCAPLUS  
 CN Benzaldehyde, 4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 199114-34-6 HCAPLUS

CN Benzaldehyde, 4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 199114-35-7 HCAPLUS

CN Benzaldehyde, 4-[2-(2-methyl-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 199114-36-8 HCAPLUS

CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)




RN 199114-37-9 HCAPLUS


CN Benzaldehyde, 4-[(3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)




RN 199114-38-0 HCAPLUS  
 CN Benzaldehyde, 4-[(1,4-dihydro-1-methyl-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)




RN 199114-39-1 HCAPLUS  
 CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-3-methoxy- (9CI) (CA INDEX NAME)




RN 199114-40-4 HCAPLUS  
 CN Benzaldehyde, 4-[(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, 1-oxime (9CI) (CA INDEX NAME)




RN 199114-41-5 HCAPLUS  
 CN 4-(3H)-Pyrimidinone, 2-ethyl-3-[(2-[(4-hydroxyamino)methyl]phenoxy)ethyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 199114-42-6 HCAPLUS  
 CN Urea, N-[4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]phenyl]methyl-N-hydroxy- (9CI) (CA INDEX NAME)




RN 199114-45-9 HCAPLUS  
 CN 4(3H)-Pyrimidinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl-6-methyl- (9CI)  
 (CA INDEX NAME)



RN 199114-46-0 HCAPLUS  
 CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl- (9CI) (CA INDEX NAME)




RN 199114-47-1 HCAPLUS  
 CN Benzenepropanoic acid,  $\alpha$ -bromo-4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 199114-48-2 HCAPLUS  
 CN Benzenepropanoic acid,  $\alpha$ -bromo-4-[2-(2-ethyl-4-oxo-3(4H)-

quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 199114-51-7 HCAPLUS

CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-alpha-hydroxy- (9CI) (CA INDEX NAME)




RN 199114-52-8 HCAPLUS

CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-alpha-hydroxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 199114-54-0 HCAPLUS

CN Benzaldehyde, 4-[2-(2,5,6-trimethyl-4-oxothieno[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 199114-56-2 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 199114-57-3 HCAPLUS

CN Benzenepropanoic acid,  $\alpha$ -bromo-4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)

=&gt; fil uspatall

FILE 'USPATFULL' ENTERED AT 15:07:43 ON 24 AUG 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 15:07:43 ON 24 AUG 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=&gt; d bib abs hitstr tot

L57 ANSWER 1 OF 9 USPATFULL on STN

AN 2003:148981 USPATFULL

TI Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases

IN Lohray, Vidya Bhushan, Hyderabad, INDIA  
Lohray, Braj Bhushan, Hyderabad, INDIA  
Paraselli, Rao Bheema, Hyderabad, INDIA  
Gurram, Ranga Madhavan, Hyderabad, INDIA  
Ramanujam, Rajagopalan, Hyderabad, INDIA  
Chakrabarti, Ranjan, Hyderabad, INDIA  
Pakala, Sarma K. S., Hyderabad, INDIA

PA Dr. Reddy's Laboratories Ltd., Hyderabad, INDIA (non-U.S. corporation)

PI US 6573268 B1 20030603

AI US 2000-535388 20000324 (9)

RLI Division of Ser. No. US 1999-353286, filed on 14 Jul 1999, now patented, Pat. No. US 6114526 Division of Ser. No. US 1997-884816, filed on 30 Jun 1997, now patented, Pat. No. US 5985884 Continuation-in-part of Ser. No. US 1996-777627, filed on 31 Dec 1996, now patented, Pat. No. US 5885997

PRAI IN 1996-115096 19960701

DT Utility

FS GRANTED

EXNAM Primary Examiner: Qazi, Sabiha

LREP Ladas &amp; Parry

CLMN Number of Claims: 8

ECL Exemplary Claim: 1

DRWN 0 Drawing Figure(s); 0 Drawing Page(s)

LN.CNT 2738

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinedione derivatives of the general formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. ##STR1##


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 199114-32-4P 199114-33-5P 199114-34-6P  
 199114-35-7P 199114-36-8P 199114-37-9P  
 199114-38-0P 199114-39-1P 199114-40-4P  
 199114-41-5P 199114-42-6P 199114-45-9P  
 199114-46-0P 199114-47-1P 199114-48-2P  
 199114-51-7P 199114-52-8P 199114-54-0P  
 199114-56-2P 199114-57-3P

(preparation of thiazolidinediones and analogs as antidiabetics)


RN 199114-32-4 USPATFULL

CN Benzaldehyde, 4- [2- (4-oxo-3 (4H) -quinazolinyl)ethoxy] - (9CI) (CA INDEX NAME)




RN 199114-33-5 USPATFULL

CN Benzaldehyde, 4- [2- (2-methyl-4-oxo-3 (4H) -quinazolinyl)ethoxy] - (9CI) (CA INDEX NAME)




RN 199114-34-6 USPATFULL

CN Benzaldehyde, 4- [2- (2-ethyl-4-oxo-3 (4H) -quinazolinyl)ethoxy] - (9CI) (CA INDEX NAME)




RN 199114-35-7 USPATFULL

CN Benzaldehyde, 4- [2- (2-methyl-4-oxopyrido[2,3-d]pyrimidin-3(4H) -yl)ethoxy] - (9CI) (CA INDEX NAME)




RN 199114-36-8 USPATFULL

CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy] - (9CI) (CA INDEX NAME)




RN 199114-37-9 USPATFULL

CN Benzaldehyde, 4-[(3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy] - (9CI) (CA INDEX NAME)




RN 199114-38-0 USPATFULL

CN Benzaldehyde, 4-[(1,4-dihydro-1-methyl-4-oxo-2-quinazolinyl)methoxy] - (9CI) (CA INDEX NAME)




RN 199114-39-1 USPATFULL


CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy] - 3-methoxy - (9CI) (CA INDEX NAME)




RN 199114-40-4 USPATFULL  
 CN Benzaldehyde, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-,  
     1-oxime (9CI) (CA INDEX NAME)




RN 199114-41-5 USPATFULL  
 CN 4(3H)-Pyrimidinone, 2-ethyl-3-[2-[4-[(hydroxyamino)methyl]phenoxy]ethyl]-6-  
     methyl- (9CI) (CA INDEX NAME)



RN 199114-42-6 USPATFULL  
 CN Urea, N-[(4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]phenyl)methyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 199114-45-9 USPATFULL  
 CN 4(3H)-Pyrimidinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl-6-methyl- (9CI)  
     (CA INDEX NAME)




RN 199114-46-0 USPATFULL


CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl- (9CI) (CA INDEX NAME)




RN 199114-47-1 USPATFULL

CN Benzenepropanoic acid,  $\alpha$ -bromo-4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)

RN 199114-48-2 USPATFULL


CN Benzenepropanoic acid,  $\alpha$ -bromo-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)

RN 199114-51-7 USPATFULL

CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)


RN 199114-52-8 USPATFULL

CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]- $\alpha$ -hydroxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 199114-54-0 USPATFULL

CN Benzaldehyde, 4-[2-(2,5,6-trimethyl-4-oxothieno[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 199114-56-2 USPATFULL

CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 199114-57-3 USPATFULL

CN Benzenepropanoic acid,  $\alpha$ -bromo-4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)

L57 ANSWER 2 OF 9 USPATFULL on STN

AN 2002:228341 USPATFULL


TI Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases

IN Lohray, Vidya Bhushan, Hyderabad, INDIA  
Lohray, Braj Bhushan, Hyderabad, INDIA  
Paraselli, Rao Bheema, Hyderabad, INDIA  
Gurram, Ranga Madhavan, Hyderabad, INDIA  
Ramanujam, Rajagopalan, Hyderabad, INDIA  
Chakrabarti, Ranjan, Hyderabad, INDIA  
Pakala, Sarma K.S., Hyderabad, INDIA


PA DR. REDDY'S RESEARCH FOUNDATION & REDDY-CHEMINOR, INC. (non-U.S.  
 corporation)  
 PI US 2002123502 A1 20020905  
 US 6780992 B2 20040824  
 AI US 2001-32846 A1 20011226 (10)  
 RLI Division of Ser. No. US 2001-827009, filed on 5 Apr 2001, PENDING  
 Division of Ser. No. US 2000-535388, filed on 24 Mar 2000, PENDING  
 Division of Ser. No. US 1999-353286, filed on 14 Jul 1999, PATENTED  
 Division of Ser. No. US 1997-884816, filed on 30 Jun 1997, PATENTED  
 Continuation-in-part of Ser. No. US 1996-777627, filed on 31 Dec 1996,  
 PATENTED  
 PRAI IN 1996-115096 19960701  
 DT Utility  
 FS APPLICATION  
 LREP LADAS & PARRY, 26 WEST 61ST STREET, NEW YORK, NY, 10023  
 CLMN Number of Claims: 25  
 ECL Exemplary Claim: 1  
 DRWN No Drawings  
 LN.CNT 2915  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB The present invention relates to novel antidiabetic compounds, their  
 tautomeric forms, their derivatives, their stereoisomers, their  
 polymorphs, their pharmaceutically acceptable salts, their  
 pharmaceutically acceptable solvates and pharmaceutically acceptable  
 compositions containing them. This invention particularly relates to  
 novel azolidinedione derivatives of the general formula (I), and their  
 pharmaceutically acceptable salts, pharmaceutically acceptable solvates  
 and pharmaceutical compositions containing them ##STR1##  
 and pharmaceutical compositions containing them ##STR1##  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 199114-32-4P 199114-33-5P 199114-34-6P  
 199114-35-7P 199114-36-8P 199114-37-9P  
 199114-38-0P 199114-39-1P 199114-40-4P  
 199114-41-5P 199114-42-6P 199114-45-9P  
 199114-46-0P 199114-47-1P 199114-48-2P  
 199114-51-7P 199114-52-8P 199114-54-0P  
 199114-56-2P 199114-57-3P  
 (preparation of thiazolidinediones and analogs as antidiabetics)

RN 199114-32-4 USPATFULL  
 CN Benzaldehyde, 4- [2- (4-oxo-3 (4H) -quinazolinyl)ethoxy] - (9CI) (CA INDEX  
 NAME)




RN 199114-33-5 USPATFULL  
 CN Benzaldehyde, 4- [2- (2-methyl-4-oxo-3 (4H) -quinazolinyl)ethoxy] - (9CI) (CA  
 INDEX NAME)




RN 199114-34-6 USPATFULL

CN Benzaldehyde, 4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 199114-35-7 USPATFULL

CN Benzaldehyde, 4-[2-(2-methyl-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 199114-36-8 USPATFULL

CN Benzaldehyde, 4-[ (3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)




RN 199114-37-9 USPATFULL

CN Benzaldehyde, 4-[ (3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)




RN 199114-38-0 USPATFULL


CN Benzaldehyde, 4-[ (1,4-dihydro-1-methyl-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)




RN 199114-39-1 USPATFULL  
 CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-3-methoxy- (9CI) (CA INDEX NAME)




RN 199114-40-4 USPATFULL  
 CN Benzaldehyde, 4-[(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-1-oxime (9CI) (CA INDEX NAME)




RN 199114-41-5 USPATFULL  
 CN 4(3H)-Pyrimidinone, 2-ethyl-3-[(2-[(4-hydroxyamino)methyl]phenoxy)ethyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 199114-42-6 USPATFULL  
 CN Urea, N-[(4-[(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]phenyl)methyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 199114-45-9 USPATFULL  
 CN 4 (3H) -Pyrimidinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl-6-methyl- (9CI)  
 (CA INDEX NAME)




RN 199114-46-0 USPATFULL  
 CN 4 (3H) -Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl- (9CI) (CA INDEX  
 NAME)




RN 199114-47-1 USPATFULL  
 CN Benzene propanoic acid,  $\alpha$ -bromo-4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 199114-48-2 USPATFULL  
 CN Benzene propanoic acid,  $\alpha$ -bromo-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-51-7 USPATFULL


CN Benzene propanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)

RN 199114-52-8 USPATFULL

CN Benzene propanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]- $\alpha$ -hydroxy-, ethyl ester (9CI) (CA INDEX NAME)


RN 199114-54-0 USPATFULL

CN Benzaldehyde, 4-[2-(2,5,6-trimethyl-4-oxothieno[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 199114-56-2 USPATFULL

CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 199114-57-3 USPATFULL


CN Benzene propanoic acid,  $\alpha$ -bromo-4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)




L57 ANSWER 3 OF 9 USPATFULL on STN  
 AN 2001:191137 USPATFULL  
 TI Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases  
 IN Lohray, Vidya Bhushan, Hyderabad, India  
 Lohray, Braj Bhushan, Hyderabad, India  
 Paraselli, Rao Bheema, Hyderabad, India  
 Gurram, Ranga Madhavan, Hyderabad, India  
 Ramanujam, Rajagopalan, Hyderabad, India  
 Chakrabarti, Ranjan, Hyderabad, India  
 Pakala, Sarma K. S., Hyderabad, India  
 PA Dr. Reddy's Research Foundation, Hyderabad, India (non-U.S. corporation)  
 Reddy-Cheminor Inc., Ridgewood, NJ, United States (U.S. corporation)  
 PI US 6310069 B1 20011030  
 AI US 2000-535387 20000324 (9)  
 RLI Continuation-in-part of Ser. No. US 1997-884816, filed on 30 Jun 1997,  
 now patented, Pat. No. US 5985884 Continuation-in-part of Ser. No. US  
 1996-777627, filed on 31 Dec 1996, now patented, Pat. No. US 5885997  
 DT Utility  
 FS GRANTED  
 EXNAM Primary Examiner: Qaz, Sabiha N.  
 LREP Ladas & Parry  
 CLMN Number of Claims: 2  
 ECL Exemplary Claim: 1  
 DRWN No Drawings  
 LN.CNT 2623  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinedione derivatives of the general formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. ##STR1##  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 IT 199114-32-4P 199114-33-5P 199114-34-6P  
 199114-35-7P 199114-36-8P 199114-37-9P  
 199114-38-0P 199114-39-1P 199114-40-4P  
 199114-41-5P 199114-42-6P 199114-45-9P  
 199114-46-0P 199114-47-1P 199114-48-2P  
 199114-51-7P 199114-52-8P 199114-54-0P  
 199114-56-2P 199114-57-3P  
 (preparation of heterocyclic compds. for the treatment of diabetes and  
 related diseases)  
 RN 199114-32-4 USPATFULL  
 CN Benzaldehyde, 4-[2-(4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX  
 NAME)




RN 199114-33-5 USPATFULL  
 CN Benzaldehyde, 4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy] - (9CI) (CA INDEX NAME)




RN 199114-34-6 USPATFULL  
 CN Benzaldehyde, 4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy] - (9CI) (CA INDEX NAME)




RN 199114-35-7 USPATFULL  
 CN Benzaldehyde, 4-[2-(2-methyl-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl)ethoxy] - (9CI) (CA INDEX NAME)




RN 199114-36-8 USPATFULL  
 CN Benzaldehyde, 4-[ (3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy] - (9CI) (CA INDEX NAME)




RN 199114-37-9 USPATFULL  
 CN Benzaldehyde, 4-[(3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy]- (9CI)  
 (CA INDEX NAME)




RN 199114-38-0 USPATFULL  
 CN Benzaldehyde, 4-[(1,4-dihydro-1-methyl-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)




RN 199114-39-1 USPATFULL  
 CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-3-methoxy- (9CI) (CA INDEX NAME)




RN 199114-40-4 USPATFULL  
 CN Benzaldehyde, 4-[(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-1-oxime (9CI) (CA INDEX NAME)




RN 199114-41-5 USPATFULL  
 CN 4-(3H)-Pyrimidinone, 2-ethyl-3-[(4-[(hydroxyamino)methyl]phenoxy)ethyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 199114-42-6 USPATFULL  
 CN Urea, N-[[4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]phenyl]methyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 199114-45-9 USPATFULL  
 CN 4(3H)-Pyrimidinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl-6-methyl- (9CI)  
 (CA INDEX NAME)




RN 199114-46-0 USPATFULL  
 CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl- (9CI) (CA INDEX NAME)




RN 199114-47-1 USPATFULL  
 CN Benzenepropanoic acid,  $\alpha$ -bromo-4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 199114-48-2 USPATFULL  
 CN Benzenepropanoic acid,  $\alpha$ -bromo-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 199114-51-7 USPATFULL  
 CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)




RN 199114-52-8 USPATFULL  
 CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]- $\alpha$ -hydroxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 199114-54-0 USPATFULL  
 CN Benzaldehyde, 4-[2-(2,5,6-trimethyl-4-oxothieno[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-56-2 USPATFULL  
 CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 199114-57-3 USPATFULL  
 CN Benzenepropanoic acid,  $\alpha$ -bromo-4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



L57 ANSWER 4 OF 9 USPATFULL on STN

AN 2001:182599 USPATFULL

TI Novel heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases

IN Lohray, Dya Bhushan, Hyderabad, India  
 Lohray, Raj Bhushan, Hyderabad, India  
 Paraselli, Rao Bheema, Hyderabad, India  
 Gurram, Ranga Madhavan, Hyderabad, India  
 Ramanujam, Rajagopalan, Hyderabad, India  
 Chakrabarti, Ranjan, Hyderabad, India  
 Pakala, Sarma K.S., Hyderabad, India

PA DR. REDDY'S RESEARCH FOUNDATION & REDDY- CHEMINOR, INC. (non-U.S. corporation)

PI US 2001031759 A1 20011018  
 US 6372750 B2 20020416

AI US 2001-827009 A1 20010405 (9)

RLI Division of Ser. No. US 2000-535388, filed on 24 Mar 2000, PENDING  
 Division of Ser. No. US 1999-353286, filed on 14 Jul 1999, GRANTED, Pat. No. US 6114526 Division of Ser. No. US 1997-884816, filed on 30 Jun 1997, GRANTED, Pat. No. US 5985884 Continuation-in-part of Ser. No. US 1996-777627, filed on 31 Dec 1996, GRANTED, Pat. No. US 5885997

PRAI IN 1996-115096 19960701

DT Utility

FS APPLICATION

LREP LADAS & PARRY, 26 WEST 61ST STREET, NEW YORK, NY, 10023

CLMN Number of Claims: 25

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2922

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinedione derivatives of the general formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 199114-32-4P 199114-33-5P 199114-34-6P  
 199114-35-7P 199114-36-8P 199114-37-9P  
 199114-38-0P 199114-39-1P 199114-40-4P  
 199114-41-5P 199114-42-6P 199114-45-9P  
 199114-46-0P 199114-47-1P 199114-48-2P


199114-51-7P 199114-52-8P 199114-54-0P

199114-56-2P 199114-57-3P

(preparation of thiazolidinediones and analogs as antidiabetics)


RN 199114-32-4 USPATFULL

CN Benzaldehyde, 4- [2- (4-oxo-3 (4H) -quinazolinyl)ethoxy] - (9CI) (CA INDEX NAME)




RN 199114-33-5 USPATFULL

CN Benzaldehyde, 4- [2- (2-methyl-4-oxo-3 (4H) -quinazolinyl)ethoxy] - (9CI) (CA INDEX NAME)




RN 199114-34-6 USPATFULL

CN Benzaldehyde, 4- [2- (2-ethyl-4-oxo-3 (4H) -quinazolinyl)ethoxy] - (9CI) (CA INDEX NAME)




RN 199114-35-7 USPATFULL

CN Benzaldehyde, 4- [2- (2-methyl-4-oxopyrido[2,3-d]pyrimidin-3 (4H) -yl)ethoxy] - (9CI) (CA INDEX NAME)




RN 199114-36-8 USPATFULL


CN Benzaldehyde, 4- [(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy] - (9CI) (CA INDEX NAME)




RN 199114-37-9 USPATFULL  
 CN Benzaldehyde, 4-[(3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy] - (9CI)  
 (CA INDEX NAME)




RN 199114-38-0 USPATFULL  
 CN Benzaldehyde, 4-[(1,4-dihydro-1-methyl-4-oxo-2-quinazolinyl)methoxy] - (9CI) (CA INDEX NAME)




RN 199114-39-1 USPATFULL  
 CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy] -3-methoxy- (9CI) (CA INDEX NAME)




RN 199114-40-4 USPATFULL  
 CN Benzaldehyde, 4-[(2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy)-1-oxime] - (9CI) (CA INDEX NAME)




RN 199114-41-5 USPATFULL  
 CN 4(3H)-Pyrimidinone, 2-ethyl-3-[2-[4-[(hydroxyamino)methyl]phenoxy]ethyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 199114-42-6 USPATFULL  
 CN Urea, N-[[4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]phenyl]methyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 199114-45-9 USPATFULL  
 CN 4(3H)-Pyrimidinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl-6-methyl- (9CI)  
 (CA INDEX NAME)




RN 199114-46-0 USPATFULL  
 CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl- (9CI) (CA INDEX NAME)




RN 199114-47-1 USPATFULL  
 CN Benzenepropanoic acid,  $\alpha$ -bromo-4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-

pyrimidinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 199114-48-2 USPATFULL

CN Benzenepropanoic acid,  $\alpha$ -bromo-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 199114-51-7 USPATFULL

CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)




RN 199114-52-8 USPATFULL

CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]- $\alpha$ -hydroxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 199114-54-0 USPATFULL

CN Benzaldehyde, 4-[2-(2,5,6-trimethyl-4-oxothieno[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 199114-56-2 USPATFULL

CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 199114-57-3 USPATFULL

CN Benzene propanoic acid,  $\alpha$ -bromo-4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)

L57 ANSWER 5 OF 9 USPATFULL on STN

AN 2000:117907 USPATFULL

TI Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases

IN Lohray, Vidya Bhushan, Hyderabad, India

Lohray, Braj Bhushan, Hyderabad, India

Paraselli, Rao Bheema, Hyderabad, India

Gurram, Ranga Madhavan, Hyderabad, India

Ramanujam, Rajagopalan, Hyderabad, India

Chakrabarti, Ranjan, Hyderabad, India

Pakala, Sarma K.S., Hyderabad, India

PA Dr. Reddy's Research Foundation, Hyderabad, India (non-U.S. corporation)

Reddy-Cheminor Inc., Ridgewood, NJ, United States (U.S. corporation)

PI US 6114526 20000905

AI US 1999-353286 19990714 (9)

RLI Continuation of Ser. No. US 1996-777627, filed on 31 Dec 1996, now patented, Pat. No. US 5885997 76 Ser. No. US 1997-884816, filed on 30 Jun 1997

PRAI IN 1996-115096 19960701

DT Utility

FS Granted

EXNAM Primary Examiner: Dees, Jose' G.; Assistant Examiner: Qazi, Sabiha N.

LREP Ladas &amp; Parry

CLMN Number of Claims: 5

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2583

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinedione derivatives of the general formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them ##STR1##


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 199114-32-4P 199114-33-5P 199114-34-6P  
 199114-35-7P 199114-36-8P 199114-37-9P  
 199114-38-0P 199114-39-1P 199114-40-4P  
 199114-41-5P 199114-42-6P 199114-45-9P  
 199114-46-0P 199114-47-1P 199114-48-2P  
 199114-51-7P 199114-52-8P 199114-54-0P  
 199114-56-2P 199114-57-3P

(preparation of thiazolidinediones and analogs as antidiabetics)


RN 199114-32-4 USPATFULL

CN Benzaldehyde, 4-[2-(4-oxo-3(4H)-quinazolinyl)ethoxy] - (9CI) (CA INDEX NAME)




RN 199114-33-5 USPATFULL

CN Benzaldehyde, 4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy] - (9CI) (CA INDEX NAME)



RN 199114-34-6 USPATFULL


CN Benzaldehyde, 4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy] - (9CI) (CA INDEX NAME)




RN 199114-35-7 USPATFULL

CN Benzaldehyde, 4-[2-(2-methyl-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl)ethoxy] -


(9CI) (CA INDEX NAME)




RN 199114-36-8 USPATFULL  
 CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy] -  
 (9CI) (CA INDEX NAME)




RN 199114-37-9 USPATFULL  
 CN Benzaldehyde, 4-[(3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy] - (9CI)  
 (CA INDEX NAME)




RN 199114-38-0 USPATFULL  
 CN Benzaldehyde, 4-[(1,4-dihydro-1-methyl-4-oxo-2-quinazolinyl)methoxy] -  
 (9CI) (CA INDEX NAME)




RN 199114-39-1 USPATFULL  
 CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy] -3-  
 methoxy - (9CI) (CA INDEX NAME)




RN 199114-40-4 USPATFULL  
 CN Benzaldehyde, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, 1-oxime (9CI) (CA INDEX NAME)




RN 199114-41-5 USPATFULL  
 CN 4(3H)-Pyrimidinone, 2-ethyl-3-[2-[4-[(hydroxyamino)methyl]phenoxy]ethyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 199114-42-6 USPATFULL  
 CN Urea, N-[[4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]phenyl]methyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 199114-45-9 USPATFULL  
 CN 4(3H)-Pyrimidinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl-6-methyl- (9CI) (CA INDEX NAME)




RN 199114-46-0 USPATFULL  
 CN 4 (3H) -Quinazolinone, 3 - [2 - (4 - aminophenoxy) ethyl] -2 -ethyl - (9CI) (CA INDEX NAME)




RN 199114-47-1 USPATFULL  
 CN Benzenepropanoic acid,  $\alpha$ -bromo-4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 199114-48-2 USPATFULL  
 CN Benzenepropanoic acid,  $\alpha$ -bromo-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-51-7 USPATFULL  
 CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)




RN 199114-52-8 USPATFULL  
 CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]- $\alpha$ -hydroxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 199114-54-0 USPATFULL

CN Benzaldehyde, 4-[(2-(2,5,6-trimethyl-4-oxothieno[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 199114-56-2 USPATFULL

CN 4(3H)-Quinazolinone, 3-[(2-(4-aminophenoxy)ethyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 199114-57-3 USPATFULL

CN Benzenepropanoic acid,  $\alpha$ -bromo-4-[(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)

L57 ANSWER 6 OF 9 USPATFULL on STN

AN 1999:146583 USPATFULL

TI Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases

IN Lohray, Vidya Bhushan, Jubilee Hills, India

Lohray, Braj Bhushan, Jubilee Hills, India

Paraselli, Rao Bheema, Miyapur, India

Gurram, Ranga Madhavan, Miyapur, India

Ramanujam, Rajagopalan, Yellareddy Guda, India

Chakrabarti, Ranjan, Nagar, India


Pakala, Sarma K. S., Kukatpally, India

PA Dr. Reddy's Research Foundation, Hyderabad, India (non-U.S. corporation)  
 Reddy-Cheminor Inc., Ridgewood, NJ, United States (U.S. corporation)  
 PI US 5985884 19991116  
 AI US 1997-884816 19970630 (8)  
 RLI Continuation-in-part of Ser. No. US 1996-777627, filed on 31 Dec 1996,  
 now patented, Pat. No. US 5885997  
 PRAI IN 1996-115096 19960701  
 DT Utility  
 FS Granted  
 EXNAM Primary Examiner: Dees, Jose' G.; Assistant Examiner: Qazi, Sabiha N.  
 LREP Ladas & Parry  
 CLMN Number of Claims: 14  
 ECL Exemplary Claim: 1  
 DRWN No Drawings  
 LN.CNT 2657


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel antidiabetic compounds, their  
 tautomeric forms, their derivatives, their stereoisomers, their  
 polymorphs, their pharmaceutically acceptable salts, their  
 pharmaceutically acceptable solvates and pharmaceutically acceptable  
 compositions containing them. This invention particularly relates to  
 novel azolidinedione derivatives of the general formula (I), and their  
 pharmaceutically acceptable salts, pharmaceutically acceptable solvates  
 and pharmaceutical compositions containing them. ##STR1##  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 199114-32-4P 199114-33-5P 199114-34-6P  
 199114-35-7P 199114-36-8P 199114-37-9P  
 199114-38-0P 199114-39-1P 199114-40-4P  
 199114-41-5P 199114-42-6P 199114-45-9P  
 199114-46-0P 199114-47-1P 199114-48-2P  
 199114-51-7P 199114-52-8P 199114-54-0P  
 199114-56-2P 199114-57-3P  
 (preparation of heterocyclic compds. for the treatment of diabetes and  
 related diseases)  
 RN 199114-32-4 USPATFULL  
 CN Benzaldehyde, 4- [2- (4-oxo-3 (4H) -quinazolinyl)ethoxy] - (9CI) (CA INDEX  
 NAME)




RN 199114-33-5 USPATFULL  
 CN Benzaldehyde, 4- [2- (2-methyl-4-oxo-3 (4H) -quinazolinyl)ethoxy] - (9CI) (CA  
 INDEX NAME)




RN 199114-34-6 USPATFULL  
 CN Benzaldehyde, 4- [2- (2-ethyl-4-oxo-3 (4H) -quinazolinyl)ethoxy] - (9CI) (CA


INDEX NAME)




RN 199114-35-7 USPATFULL  
 CN Benzaldehyde, 4-[(2-(2-methyl-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl)ethoxy] -  
 (9CI) (CA INDEX NAME)




RN 199114-36-8 USPATFULL  
 CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy] -  
 (9CI) (CA INDEX NAME)




RN 199114-37-9 USPATFULL  
 CN Benzaldehyde, 4-[(3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy] - (9CI)  
 (CA INDEX NAME)




RN 199114-38-0 USPATFULL  
 CN Benzaldehyde, 4-[(1,4-dihydro-1-methyl-4-oxo-2-quinazolinyl)methoxy] -  
 (9CI) (CA INDEX NAME)




RN 199114-39-1 USPATFULL  
 CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-3-methoxy- (9CI) (CA INDEX NAME)




RN 199114-40-4 USPATFULL  
 CN Benzaldehyde, 4-[(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-1-oxime (9CI) (CA INDEX NAME)




RN 199114-41-5 USPATFULL  
 CN 4-(3H)-Pyrimidinone, 2-ethyl-3-[(2-[(hydroxyamino)methyl]phenoxy]ethyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 199114-42-6 USPATFULL  
 CN Urea, N-[(4-[(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]phenyl)methyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 199114-45-9 USPATFULL  
 CN 4(3H)-Pyrimidinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl-6-methyl- (9CI)  
 (CA INDEX NAME)




RN 199114-46-0 USPATFULL  
 CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl- (9CI) (CA INDEX NAME)




RN 199114-47-1 USPATFULL  
 CN Benzenepropanoic acid,  $\alpha$ -bromo-4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 199114-48-2 USPATFULL  
 CN Benzenepropanoic acid,  $\alpha$ -bromo-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-51-7 USPATFULL


CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)

RN 199114-52-8 USPATFULL

CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]- $\alpha$ -hydroxy-, ethyl ester (9CI) (CA INDEX NAME)


RN 199114-54-0 USPATFULL

CN Benzaldehyde, 4-[2-(2,5,6-trimethyl-4-oxothieno[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 199114-56-2 USPATFULL

CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 199114-57-3 USPATFULL

CN Benzenepropanoic acid,  $\alpha$ -bromo-4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



L57 ANSWER 7 OF 9 USPATFULL on STN

AN 1999:37111 USPATFULL

TI Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases

IN Lohray, Vidya Bhushan, Hyderabad, India  
Lohray, Braj Bhushan, Hyderabad, India

Paraselli, Rao Bheema, Hyderabad, India

PA Dr. Reddy's Research Foundation, Hyderabad, India (non-U.S. corporation)  
Reddy-Cheminor, Inc., Ridgewood, NJ, United States (U.S. corporation)

PI US 5885997 19990323

AI US 1996-777627 19961231 (8)

PRAI IN 1996-115096 19960701

DT Utility

FS Granted

EXNAM Primary Examiner: Dees, Jose G.; Assistant Examiner: Oazi, Sabiha N.

LREP Ladas & Parry

CLMN Number of Claims: 16

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1914

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinedione derivatives of the general formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. ##STR1##


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 199114-32-4P 199114-33-5P 199114-34-6P  
199114-35-7P 199114-36-8P 199114-37-9P  
199114-38-0P 199114-39-1P 199114-40-4P  
199114-41-5P 199114-42-6P 199114-45-9P  
199114-46-0P 199114-47-1P 199114-48-2P  
199114-51-7P 199114-52-8P 199114-54-0P

(preparation of pyrimidinylethoxybenzylthiazolidinediones)


RN 199114-32-4 USPATFULL

CN Benzaldehyde, 4-[2-(4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX  
NAME)




RN 199114-33-5 USPATFULL

CN Benzaldehyde, 4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 199114-34-6 USPATFULL

CN Benzaldehyde, 4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 199114-35-7 USPATFULL

CN Benzaldehyde, 4-[2-(2-methyl-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 199114-36-8 USPATFULL

CN Benzaldehyde, 4-[ (3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)




RN 199114-37-9 USPATFULL


CN Benzaldehyde, 4-[ (3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)




RN 199114-38-0 USPATFULL  
 CN Benzaldehyde, 4-[(1,4-dihydro-1-methyl-4-oxo-2-quinazolinyl)methoxy] -  
 (9CI) (CA INDEX NAME)




RN 199114-39-1 USPATFULL  
 CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy] -3-  
 methoxy- (9CI) (CA INDEX NAME)




RN 199114-40-4 USPATFULL  
 CN Benzaldehyde, 4-[(2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy] -  
 1-oxime (9CI) (CA INDEX NAME)




RN 199114-41-5 USPATFULL  
 CN 4(3H)-Pyrimidinone, 2-ethyl-3-[(2-[(4-[(hydroxyamino)methyl]phenoxy]ethyl)-6-  
 methyl- (9CI) (CA INDEX NAME)




RN 199114-42-6 USPATFULL  
 CN Urea, N-[4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]phenyl]methyl-N-hydroxy- (9CI) (CA INDEX NAME)




RN 199114-45-9 USPATFULL  
 CN 4(3H)-Pyrimidinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl-6-methyl- (9CI) (CA INDEX NAME)



RN 199114-46-0 USPATFULL  
 CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl- (9CI) (CA INDEX NAME)




RN 199114-47-1 USPATFULL  
 CN Benzene propanoic acid, alpha-bromo-4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 199114-48-2 USPATFULL  
 CN Benzene propanoic acid, alpha-bromo-4-[2-(2-ethyl-4-oxo-3(4H)-

quinazolinyl)ethoxy] -, ethyl ester (9CI) (CA INDEX NAME)




RN 199114-51-7 USPATFULL

CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-alpha-hydroxy- (9CI) (CA INDEX NAME)




RN 199114-52-8 USPATFULL

CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-alpha-hydroxy-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-54-0 USPATFULL

CN Benzaldehyde, 4-[2-(2,5,6-trimethyl-4-oxothieno[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)



L57 ANSWER 8 OF 9 USPAT2 on STN

AN 2002:228341 USPAT2

TI Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases

IN Lohray, Vidya Bhushan, Hyderabad, INDIA  
 Lohray, Braj Bhushan, Hyderabad, INDIA  
 Paraselli, Rao Bheema, Hyderabad, INDIA  
 Gurram, Ranga Madhavan, Hyderabad, INDIA  
 Ramanujam, Rajagopalan, Hyderabad, INDIA

PA Chakrabarti, Ranjan, Hyderabad, INDIA  
 PA Pakala, Sarma K.S., Hyderabad, INDIA  
 Dr. Reddy's Laboratories Ltd., Hyderabad, INDIA (non-U.S. corporation)  
 Dr. Reddy's Laboratories Inc., Bridgewater, NJ, United States (U.S. corporation)

PI US 6780992 B2 20040824

AI US 2001-32846 20011226 (10)

RLI Division of Ser. No. US 2001-827009, filed on 5 Apr 2001, now patented, Pat. No. US 6372750 Division of Ser. No. US 2000-535388, filed on 24 Mar 2000 Division of Ser. No. US 1999-353286, filed on 14 Jul 1999, now patented, Pat. No. US 6114526 Division of Ser. No. US 1997-884816, filed on 30 Jun 1997, now patented, Pat. No. US 5985884 Continuation-in-part of Ser. No. US 1996-777627, filed on 31 Dec 1996, now patented, Pat. No. US 5885997

PRAI IN 1996-115096 19960701

DT Utility

FS GRANTED

EXNAM Primary Examiner: Qazi, Sabiha

LREP Ladas & Parry

CLMN Number of Claims: 2

ECL Exemplary Claim: 1

DRWN 0 Drawing Figure(s); 0 Drawing Page(s)

LN.CNT 2537

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinedione derivatives of the general formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 199114-32-4P 199114-33-5P 199114-34-6P  
 199114-35-7P 199114-36-8P 199114-37-9P  
 199114-38-0P 199114-39-1P 199114-40-4P  
 199114-41-5P 199114-42-6P 199114-45-9P  
 199114-46-0P 199114-47-1P 199114-48-2P  
 199114-51-7P 199114-52-8P 199114-54-0P  
 199114-56-2P 199114-57-3P  
 (preparation of thiazolidinediones and analogs as antidiabetics)


RN 199114-32-4 USPAT2

CN Benzaldehyde, 4- [2- (4-oxo-3 (4H) -quinazolinyl)ethoxy] - (9CI) (CA INDEX NAME)




RN 199114-33-5 USPAT2


CN Benzaldehyde, 4- [2- (2-methyl-4-oxo-3 (4H) -quinazolinyl)ethoxy] - (9CI) (CA INDEX NAME)




RN 199114-34-6 USPAT2  
 CN Benzaldehyde, 4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 199114-35-7 USPAT2  
 CN Benzaldehyde, 4-[2-(2-methyl-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 199114-36-8 USPAT2  
 CN Benzaldehyde, 4-[ (3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)




RN 199114-37-9 USPAT2  
 CN Benzaldehyde, 4-[ (3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)




RN 199114-38-0 USPAT2  
 CN Benzaldehyde, 4-[(1,4-dihydro-1-methyl-4-oxo-2-quinazolinyl)methoxy] -  
 (9CI) (CA INDEX NAME)




RN 199114-39-1 USPAT2  
 CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy] -3-  
 methoxy- (9CI) (CA INDEX NAME)




RN 199114-40-4 USPAT2  
 CN Benzaldehyde, 4-[(2-[(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-1-oxime (9CI) (CA INDEX NAME)




RN 199114-41-5 USPAT2  
 CN 4(3H)-Pyrimidinone, 2-ethyl-3-[(2-[(hydroxyamino)methyl]phenoxy)ethyl]-6-  
 methyl- (9CI) (CA INDEX NAME)




RN 199114-42-6 USPAT2  
 CN Urea, N-[(4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]phenyl)methyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 199114-45-9 USPAT2  
 CN 4(3H)-Pyrimidinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl-6-methyl- (9CI) (CA INDEX NAME)



RN 199114-46-0 USPAT2  
 CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl- (9CI) (CA INDEX NAME)




RN 199114-47-1 USPAT2  
 CN Benzene propanoic acid,  $\alpha$ -bromo-4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 199114-48-2 USPAT2  
 CN Benzene propanoic acid,  $\alpha$ -bromo-4-[2-(2-ethyl-4-oxo-3(4H)-

quinazolinyl)ethoxy] -, ethyl ester (9CI) (CA INDEX NAME)




RN 199114-51-7 USPAT2

CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-alpha-hydroxy- (9CI) (CA INDEX NAME)




RN 199114-52-8 USPAT2

CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-alpha-hydroxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 199114-54-0 USPAT2

CN Benzaldehyde, 4-[2-(2,5,6-trimethyl-4-oxothieno[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 199114-56-2 USPAT2

CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 199114-57-3 USPAT2

CN Benzene propanoic acid,  $\alpha$ -bromo-4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)

L57 ANSWER 9 OF 9 USPAT2 on STN

AN 2001:182599 USPAT2

TI Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases

IN Lohray, Vidya Bhushan, Hyderabad, INDIA  
Lohray, Braj Bhushan, Hyderabad, INDIA  
Paraselli, Rao Bheema, Hyderabad, INDIA  
Gurram, Ranga Madhavan, Hyderabad, INDIA  
Ramanujam, Rajagopalan, Hyderabad, INDIA  
Chakrabarti, Ranjan, Hyderabad, INDIA  
Pakala, Sarma K. S., Hyderabad, INDIAPA Dr. Reddy's Research Foundation, Hyderabad, INDIA (non-U.S. corporation)  
Reddy-Cheminor, Inc., Upper Saddle River, NJ, United States (U.S. corporation)

PI US 6372750 B2 20020416

AI US 2001-827009 20010405 (9)

RLI Division of Ser. No. US 2000-535388, filed on 24 Mar 2000 Division of Ser. No. US 1999-353286, filed on 14 Jul 1999, now patented, Pat. No. US 6114526 Division of Ser. No. US 1997-884816, filed on 30 Jun 1997, now patented, Pat. No. US 5985884 Division of Ser. No. US 1996-777627, filed on 31 Dec 1996, now patented, Pat. No. US 5885997

PRAI IN 1996-115096 19960701

DT Utility

FS GRANTED

EXNAM Primary Examiner: Qazi, Sabiha

LREP Ladas &amp; Parry

CLMN Number of Claims: 2

ECL Exemplary Claim: 1

DRWN 0 Drawing Figure(s); 0 Drawing Page(s)

LN.CNT 2653

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinedione derivatives of the general formula (I), and their

pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them ##STR1##


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 199114-32-4P 199114-33-5P 199114-34-6P  
 199114-35-7P 199114-36-8P 199114-37-9P  
 199114-38-0P 199114-39-1P 199114-40-4P  
 199114-41-5P 199114-42-6P 199114-45-9P  
 199114-46-0P 199114-47-1P 199114-48-2P  
 199114-51-7P 199114-52-8P 199114-54-0P  
 199114-56-2P 199114-57-3P

(preparation of thiazolidinediones and analogs as antidiabetics)


RN 199114-32-4 USPAT2

CN Benzaldehyde, 4- [2- (4-oxo-3 (4H) -quinazolinyl)ethoxy] - (9CI) (CA INDEX NAME)




RN 199114-33-5 USPAT2

CN Benzaldehyde, 4- [2- (2-methyl-4-oxo-3 (4H) -quinazolinyl)ethoxy] - (9CI) (CA INDEX NAME)




RN 199114-34-6 USPAT2

CN Benzaldehyde, 4- [2- (2-ethyl-4-oxo-3 (4H) -quinazolinyl)ethoxy] - (9CI) (CA INDEX NAME)




RN 199114-35-7 USPAT2


CN Benzaldehyde, 4- [2- (2-methyl-4-oxopyrido[2,3-d]pyrimidin-3 (4H) -yl)ethoxy] - (9CI) (CA INDEX NAME)




RN 199114-36-8 USPAT2  
 CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy] -  
 (9CI) (CA INDEX NAME)




RN 199114-37-9 USPAT2  
 CN Benzaldehyde, 4-[(3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy] - (9CI)  
 (CA INDEX NAME)



RN 199114-38-0 USPAT2  
 CN Benzaldehyde, 4-[(1,4-dihydro-1-methyl-4-oxo-2-quinazolinyl)methoxy] -  
 (9CI) (CA INDEX NAME)




RN 199114-39-1 USPAT2  
 CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-3-methoxy - (9CI) (CA INDEX NAME)




RN 199114-40-4 USPAT2  
 CN Benzaldehyde, 4-[(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy] -


1-oxime (9CI) (CA INDEX NAME)




RN 199114-41-5 USPAT2  
 CN 4 (3H)-Pyrimidinone, 2-ethyl-3-[2-[4-[(hydroxyamino)methyl]phenoxy]ethyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 199114-42-6 USPAT2  
 CN Urea, N-[[4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]phenyl]methyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 199114-45-9 USPAT2  
 CN 4 (3H)-Pyrimidinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl-6-methyl- (9CI) (CA INDEX NAME)




RN 199114-46-0 USPAT2  
 CN 4 (3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl- (9CI) (CA INDEX NAME)




RN 199114-47-1 USPAT2

CN Benzene propanoic acid,  $\alpha$ -bromo-4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)


RN 199114-48-2 USPAT2

CN Benzene propanoic acid,  $\alpha$ -bromo-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)

RN 199114-51-7 USPAT2


CN Benzene propanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)

RN 199114-52-8 USPAT2


CN Benzene propanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]- $\alpha$ -hydroxy-, ethyl ester (9CI) (CA INDEX NAME)

RN 199114-54-0 USPAT2


CN Benzaldehyde, 4-[2-(2,5,6-trimethyl-4-oxothieno[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-56-2 USPAT2  
 CN 4 (3H) -Quinazolinone, 3- [2- (4-aminophenoxy)ethyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 199114-57-3 USPAT2  
 CN Benzenepropanoic acid,  $\alpha$ -bromo-4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



=>